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Blood glucose levels are tightly regulated as a part of metabolic homeostasis. Mean 
normal blood glucose levels in humans are about 90 mg/dl, equivalent to 5 mmol/l. 
Glucose levels rise after meals for an hour or two by a few mmol and are usually lowest in 
the morning, before the first meal of the day. Transported via the bloodstream from the 
intestines or liver to body cells, glucose is the primary source of energy for body cells, fats 
and lipids being primarily a compact energy store. Failure to maintain blood glucose in the 
normal range leads to conditions of persistently low (hypoglycemia) or high 
(hyperglycemia) blood sugar. Since the brain functions on glucose, hypoglycemia is 
dangerous and can cause seizures, loss of consciousness, and death. Hyperglycemia, on 
the other hand, can lead to dehydration and hyper-osmolality, which can eventually result 
in a coma. Chronic hyperglycemia at levels more than slightly above normal can produce a 
very wide variety of serious complications over a period of years, including kidney 
damage, neurological damage, cardiovascular damage, and loss of vision.  
 Normal glucose homeostasis is regulated by endogenous glucose production and 
the uptake and utilization of glucose by peripheral tissues. In the fasted state glucose is 
mainly derived from the liver by 2 pathways, glycogenolysis and gluconeogenesis. 
Glycogenolysis is the biochemical breakdown of stored glycogen to glucose, while 
gluconeogenesis is the process of generating new glucose molecules from precursor 
molecules like amino acids, lactate, and glycerol. Glucose disposal takes place in 
peripheral tissues like skeletal muscle, adipose tissue, and heart tissue. The initial fate of 
glucose in tissues is essentially limited to glycolysis (catabolism of glucose) and direct 
storage either as glycogen or as the glycerol moiety of triglycerides in adipose tissue. The 
latter, however, accounts for only about 5% of postprandial glucose disposal, whereas 
liver and muscle are the sites of glycogen formation. 
 The homeostatic mechanism which keeps the blood value of glucose in a narrow 
range is composed of several interacting systems, of which hormone regulation is the 
most important. Two types of mutually antagonistic metabolic hormones affect blood 
glucose levels; they include the catabolic hormones (such as glucagon), and the anabolic 
hormone insulin. Insulin secretion by the pancreatic β-cells is stimulated after a meal. 
Then, insulin inhibits glycogenolysis and gluconeogenesis, and as a result inhibits 
endogenous glucose production. In addition, insulin stimulates glucose disposal in 
peripheral tissues. The net result of these actions of insulin is a decrease in plasma glucose 
levels. In response, glucagon is secreted by the pancreatic α-cells, which stimulates 
glycogenolysis and glucose production by the liver. Collectively with the interplay of other 
catabolic hormones (like growth hormone, cortisol, and catecholamine), endogenous 




Type 2 diabetes mellitus 
Type 2 diabetes mellitus (T2DM) has become a global epidemic rapidly. Now the disease 
affects 171 million individuals globally with an estimated mortality of about 4 million 
deaths each year
1
. Having T2DM increases the risk for complications including heart 
disease, retinopathy, neuropathy, and nephropathy. T2DM has become one of the major 
causes of premature illness and death, mainly through the increased risk for 
cardiovascular disease. The World Health Organization (WHO) predicts that diabetes 
deaths will increase by more than 50% worldwide in the next 10 years. T2DM is a chronic, 
multifactorial disease characterized by a combination of impaired insulin secretion by the 
pancreatic β-cells and insulin resistance of target organs, leading to hyperglycemia. The 
diagnosis of having diabetes mellitus is based on WHO recommendations from 2006. 
Criteria include fasting plasma glucose levels ≥ 7.0 mmol/l or 2-h plasma glucose levels ≥ 
11.1 mmol/l after a glucose load
1
.  
 The development of T2DM is the result of both a deficient insulin secretion and 
insulin resistance. Insulin resistance is a state of reduced sensitivity in peripheral tissues of 
the body to the action of insulin
2
. Muscle and adipose tissue in particular display a 
decreased responsiveness to insulin mediated glucose disposal. Resistance of the liver to 
the effects of insulin will increase endogenous glucose production. In the early stage of 
the development of T2DM, insulin resistance leads to an increase in insulin secretion by 
the β-cells to overcome the impairment of glucose disposal and endogenous glucose 
production and thereby maintaining normal glucose levels. Later in the development β-
cells fail to compensate, leading to progressive hyperglycemia and ultimately T2DM
3, 4
. 
 Consequences of insulin resistance can be viewed in two ways. First, during 
fasting, the liver represents a major site of insulin resistance, which is reflected by 
overproduction of glucose despite presence of both fasting hyperinsulinemia and 
hyperglycemia. This accelerated rate of hepatic glucose output is the primary determinant 
of elevated fasting plasma glucose concentration in T2DM. Second, with eating, failure of 
adequate insulin-mediated nutrient disposal into skeletal and adipose tissue combined 
with an attenuated inhibition of hepatic glucose production cause the raised postprandial 
glycemia. 
 
T2DM and lipid metabolism  
Besides glucose metabolism, lipid metabolism is also disturbed in T2DM patients. 
Increased plasma levels of triglycerides (TG) in very low density lipoproteins (VLDL) are 
characteristic of the dyslipidemia associated with insulin resistance and T2DM. 




process, results in low levels of high density lipoprotein cholesterol and the generation of 
small, dense, cholesterol ester depleted low density lipoproteins. Increased assembly and 
secretion of VLDL by the liver results from the complex, post-transcriptional regulation of 
apolipoprotein B (apoB) metabolism in the liver. In the presence of low levels of hepatic 
TG and cholesterol, much of the constitutively synthesized apoB is degraded by both 
proteosomal and non-proteosomal pathways. When excess TG, and to a lesser extent, 
cholesterol, are present, apoB is targeted for secretion. The major sources of TG in the 
liver: uptake of fatty acids (FA) released by lipolysis of adipose tissue TG, uptake of TG in 
VLDL and chylomicrons remnants, and hepatic de novo lipogenesis (the synthesis of FA 
from glucose) are all abnormally increased in insulin resistance.  
 
Obesity  
Body Mass Index (BMI) is a simple index of weight-for-height that is commonly used to 
classify underweight, overweight and obesity in adults. It is defined as the weight in 
kilograms divided by the square of the height in meters (kg/m
2
). Overweight is defined 
when BMI is ≥ 25 kg/m
2
 and obese when ≥ 30 kg/m
2
. The prevalence of obesity has 
reached epidemic proportions for a number of years now. Recent numbers from the WHO 
show that more than 1 billion adults are overweight worldwide
1
. In the Netherlands, 
46.9% of the total population is overweight of which 11.1% is obese. A dramatic increase 
has been found in the percentages of obese youngsters (age 15-25)
5
. Overweight and 
obesity lead to serious health consequences. They are a major risk factor for developing 
chronic diseases like cardiovascular disease, some type of cancers, musculoskeletal 
disorders, and T2DM. 
 Obesity, and in particular visceral adiposity, is negatively correlated with insulin 
sensitivity. With respect to visceral adiposity, a great deal of evidence suggests two strong 
links with insulin resistance. First, visceral adipose cells produce significant amounts of 
proinflammatory cytokines such as tumor necrosis factor-alpha, and interleukins-1 and -6, 
resistin, and leptin. In numerous experimental models, these proinflammatory cytokines 
profoundly disrupt normal insulin action in fat and muscle cells, and may be a major factor 
in causing the whole-body insulin resistance observed in patients with visceral adiposity
6, 
7
. Second, visceral adiposity is related to an accumulation of hepatic fat stores, a condition 
known as nonalcoholic fatty liver disease (NAFLD). The result of NAFLD is an excessive 
release of FFA into the bloodstream (due to increased lipolysis), and an increase in hepatic 
glucose production, both of which have the effect of exacerbating peripheral insulin 







Therapies for T2DM 
T2DM and obesity associated insulin resistance impose a major health risk, due to 
increased morbidity and mortality. The major goal of therapeutic intervention is to 
ameliorate hyperglycemia and insulin resistance, but also increased risk factors such as 
dyslipidemia and hypertension should be taken into account. Without medication, the 
outcome of the disease can significantly be improved by lifestyle changes. Restricted 
caloric intake, weight loss, and exercise will significantly improve whole body insulin 
sensitivity
9, 10
. Sometimes, these adaptations are not enough to reduce blood glucose 
levels near the normal range. In addition, lifestyle changes are not easy and require a 
strong will. Moreover, it has to be continued for a long term, since weight gain and 
symptoms of T2DM will come back once discontinued. Therefore, the need for 
pharmacological strategies is required. Sulfonylureas, meglitinides, biguanides, 
thiazolidinediones, and alpha-glucosidase inhibitors comprise classes of drugs that lower 
blood glucose levels. Because these drugs work in different ways to accomplish this, they 
may be used together to get the desired effects. However, taking more than one drug is 
more costly and can increase the risk of side effects. Recently, the gut hormones have 
become interesting therapeutic targets in the battle against T2DM, because of their 
effects on both food intake and glucose metabolism.  
 
Gut-brain axis  
The gastrointestinal tract is the largest endocrine organ in the body and releases more 
than 20 different regulatory peptide hormones that influence a number of physiological 
processes and act on tissues including exocrine glands, smooth muscle, and the central 
nervous system. Most of the gut hormones are sensitive to gut nutrient content, and 
short-term feelings of hunger and satiety are believed to be mediated, in part, by 
coordinated changes in circulating gut hormone levels. The interaction between the gut 
hormones and the central nervous system, the gut-brain axis, is regulated via both 
hormonal and neuronal pathways. At the base of the third ventricle these hormones can 
cross the semi-permeable blood-brain-barrier to reach the hypothalamus. Alternatively, 
they act indirectly by altering the activity of afferent neuronal pathways and brain stem 
circuits, which in turn project to the hypothalamus.  
 The hypothalamus is regarded as the main feeding center of the brain and 
consists of several nuclei involved in food intake, including the arcuate nucleus (ARC), the 
paraventricular nucleus, the lateral hypothalamic area, the ventromedial nucleus, and the 
dorsomedial nucleus. The ARC located in the hypothalamus is the most important center 




energy balance: the orexigenic pathway, containing neurons co-expressing neuropeptide Y 
and agouti-related protein, stimulating food intake, and the anorexigenic pathway, 
containing neurons co-expressing pro-opiomelanocortin and cocaine- and amphetamine-
regulated transcript, inhibiting food intake
11
.  
 Over the past decades the pathways of food intake by the gut-brain axis have 
become increasingly well delineated
12
. Recently, compelling evidence indicates that the 
gut-brain axis is also a key partner of glucose homeostasis. This is accomplished via brain 
pathways that overlap with those controlling food intake and body weight. The gut 
hormones have emerged as key factors able to convey metabolic information to the brain 
and also to modulate endogenous glucose production and disposal
13, 14
. The present thesis 
deals with a variety of gut hormones, of which their effects on food intake and glucose 
metabolism will be summarized. 
 
Glucagon-like peptide-1 (GLP-1) is a cleavage product of the proglucagon molecule which 
is secreted by the intestinal L-cells and in the brain
15, 16
. It is released in response to food 
intake in proportion to caloric content to stimulate glucose-dependent insulin secretion
15, 
17
. In addition, GLP-1 exerts multiple other effects, including inhibition of food intake, 
slowing of gastric emptying, and inhibition of glucagon secretion
18, 19
. GLP-1 is also known 
to beneficially affect glucose metabolism in T2DM patients
19, 20
. However, GLP-1 is easily 
degraded by the enzyme dipeptidyl-peptidase IV (DPP-IV), limiting its therapeutic 
efficacy
21
. Therefore, pharmaceutical companies are developing GLP-1 analogues resistant 
to inactivation by DPP-IV. Clinical studies have shown that these analogues are very 
effective in reducing body weight and improving glucose metabolism in patients with 
T2DM. Exenatide is a synthetic version of exendin-4, a naturally-occurring GLP-1 analogue, 
which was first isolated from the saliva of the lizard known as the Gila monster. Exenatide, 
currently on the market (brand name Byetta), works to lower blood glucose levels 
primarily by increasing insulin secretion. Because it exerts this effect only in the presence 
of elevated blood glucose levels, it does not tend to increase the risk of hypoglycemia on 
its own, although hypoglycemia can occur if taken in conjunction with a sulfonylurea. The 
primary side effect is nausea, which tends to improve over time. Another class of 
medications called DPP-IV inhibitors work by preventing the breakdown of GLP-1. By 
interfering in the process that breaks down GLP-1, DPP-IV inhibitors allow it to remain 
active in the body for a longer duration, lowering blood glucose levels only when they are 
elevated. DPP-IV inhibitors do not tend to cause weight gain and tend to have a neutral or 
positive effect on cholesterol levels. Sitagliptin (Januvia) is currently the only DPP-IV 




 The anorexic effect of GLP-1 is mediated via the GLP-1 receptor in the brain
18
. 
Recent findings provide evidence linking GLP-1 action in the brain with the peripheral 
control of glucose flux, insulin sensitivity and insulin secretion
22
. Complementary studies 
reveal that the arcuate GLP-1 receptors regulate glucose homeostasis but not food 
intake
23





Oxyntomodulin (OXM) is, just like GLP-1, a cleavage product of the proglucagon molecule 
secreted from the intestinal L-cells in response to food intake in proportion to caloric 
content
25, 26
. It potently inhibits meal-stimulated gastric acid and enzyme secretion in 
rodents and man
27
. OXM is insulinotropic, however, as a circulating hormone in humans, 
its concentration is probably too low to influence insulin secretion under physiological 
circumstances
28, 29
. OXM is a potential regulator of appetite and body weight, when 
administered both intracerebroventricular and intraperitoneal in fasted rats
30, 31
. It is 
suggested that OXM causes these anorexigenic effects by affecting the arcuate nucleus in 
the brain.   
 
Peptide YY (PYY) is produced and released from the L-cells postprandially
32
. Most of the 
circulating PYY is the truncated form of the full length peptide, PYY3-36. PYY3-36 is 
transported to the brain via the blood-brain-barrier. There, it binds the Y2 receptor, which 
is expressed on NPY neurons of the arcuate nucleus, resulting in decreased food intake
33
. 
Peripheral administration of PYY3-36 has been shown to regulate long-term body weight 
reduction
34, 35
. In addition, PYY3-36 administration to mice shows an improvement of insulin 





Pancreatic polypeptide (PP) is synthesized in the so-called F-cells, located in the 
pancreatic islet of Langerhans. PP is the endogenous ligand for the Y4 receptor in the 
brain. Peripheral administration of PP has been shown to reduce food intake in both 
rodents and humans
37, 38
. Chronic treatment with PP ameliorates insulin resistance as 





Outline of the thesis 
The aim of the present thesis was to gain more insight into the potential of gut hormones 




 Chapter 2 describes the metabolic effects of peripheral administration of OXM in 
insulin resistant mice. OXM appears to be an effective regulator of food intake and 
appetite. OXM probably impacts on food intake via neural routes in the ARC, which are 
similarly engaged by other gut-derived peptides modulating appetite, like GLP-1, ghrelin, 
and PYY3-36. These peptides affect insulin sensitivity via mechanistic routes that are 
independent of food intake and body weight. Therefore, we speculated that OXM could 
also impact on insulin action in insulin resistant mice. 
 In chapter 3, we evaluated the effects of a novel GLP-1 analogue, CNTO736, on 
insulin sensitivity of glucose and VLDL metabolism in high-fat-fed mice. GLP-1 appears to 
be a promising drug target for the treatment of T2DM, however its therapeutic potency is 
limited by its short half-life. CNTO736 has an increased half-life over GLP-1 and has been 
shown to retain GLP-1-like biological activity. The aim of our study was to evaluate the 
potential of this analogue in terms of its metabolic effects. 
 In chapter 4, we further investigated the potential of the GLP-1 analogue 
described in chapter 3 to modulate lipid metabolism. Lipid metabolism is also disturbed in 
patients with T2DM. Increased VLDL-TG concentrations and decreased HDL cholesterol in 
plasma significantly contribute to the long term risk of macrovascular disease in these 
patients. We explored the chronic effects of the analogue on lipid metabolism in APOE*3-
Leiden transgenic mice, a “human-like” animal model for studies evaluating the impact of 
drugs on hyperlipidemia. 
 GLP-1 improves insulin sensitivity in humans and rodents. It is currently unknown 
to what extent the (metabolic) effects of circulating GLP-1 are mediated by central GLP-1 
receptors. Therefore, in chapter 5 we aimed to evaluate the impact of blocking central 
GLP-1 receptors on the metabolic effects of peripherally administered GLP-1. 
 Chapter 6 describes the effects of chronic treatment with the novel compounds 
Obinepitide, a synthetic analogue of PYY3-36 and PP, and TM30339, a synthetic analogue of 
PP. Both compounds, designed as anti-obesity drugs, show reduced food intake and long-
term body weight reduction. We administered the compounds for 4 weeks 
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We evaluated the acute effects of oxyntomodulin (OXM), a proglucagon derived peptide, 
on glucose metabolism in diet-induced insulin resistant male C57Bl/6 mice. To determine 
the effects on glucose tolerance, mice were intraperitoneally injected with OXM (0.75, 2.5, 
or 7.5 nmol) or vehicle prior to an intraperitoneal glucose tolerance test. 0.75 nmol/h 
OXM or vehicle was infused during a hyperinsulinemic euglycemic clamp to quantify 
insulin action on glucose production and disposal. OXM dose-dependently improved 
glucose tolerance as estimated by the area under the curve (AUC) for glucose (OXM, 7.5 
nmol: 1564 ± 460, p<0.01; 2.5 nmol: 1828 ± 684, p<0.01; 0.75 nmol: 2322 ± 303, p<0.05; 
control: 2790 ± 222 mmol/l/120 min). Insulin levels in response to glucose administration 
were higher in 7.5 nmol OXM-treated animals compared to controls (AUCinsulin: 343 ± 113 
vs. 231 ± 39 ng/ml/120 min, p<0.05). In basal clamp conditions, OXM increased 
endogenous glucose production (82.2 ± 14.7 vs. 39.9 ± 5.7 µmol/min/kg, p<0.001). During 
insulin infusion, insulin levels were twice as high in OXM-treated mice compared to 
controls (10.6 ± 2.8 vs. 4.4 ± 2.2 ng/ml, p<0.01). Consequently, glucose infusion rate (118.6 
± 30.8 vs. 38.8 ± 26.4 µl/h, p<0.001) and glucose disposal (88.1 ± 13.0 vs. 45.2 ± 6.9 
µmol/min/kg, p<0.001) were enhanced in mice that received OXM. In addition, glucose 
production was more suppressed during OXM infusion (35.7 ± 15.5 vs. 15.8 ± 11.4% 
inhibition, p<0.05). However, if these data were expressed per unit concentration of 
circulating insulin, OXM did not affect insulin action on glucose disposal and production. 
These results indicate that OXM beneficially affects glucose metabolism in diet-induced 
insulin resistant C57Bl/6 mice. It ameliorates glucose intolerance, most likely because it 
elevates glucose-induced plasma insulin concentrations. OXM does not appear to impact 
on insulin action. 
 




Posttranslational processing of proglucagon in the intestine and the central nervous 
system (CNS) yields glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), 
glicentin, and oxyntomodulin (OXM)
1-3
. OXM contains 37-amino acids, including the 
complete glucagon sequence with a basic octapeptide carboxyterminal extension
4
. OXM is 
released from intestinal L-cells into the blood in response to food ingestion in amounts 
proportional to caloric content
5, 6
. It potently inhibits meal-stimulated gastric acid and 
enzyme secretion in rodents and man
7
.  
 OXM appears to be an effective regulator of appetite and body weight. 
Intravenous (i.v.) infusion of OXM suppresses appetite and reduces food intake in humans 
during a buffet meal
8
. Furthermore, both intracerebroventricular and intraperitoneal (i.p.) 
administration of OXM reduces food intake and body weight gain during refeeding in 
fasted rats
9, 10
. OXM most likely causes these anorexigenic effects by modulating neuronal 
activity in the arcuate nucleus (ARC) of the hypothalamus
10
. OXM-like immunoreactivity 
has been found in the CNS, particularly in the hypothalamus
11, 12
, and i.p. administration of 
OXM inhibits neuronal activity in the ARC as detected by magnetic resonance imaging
13
. A 
distinct receptor for OXM has not been identified to date. However, OXM can bind to both 
the glucagon and GLP-1 receptor, which is to be expected on the basis of its molecular 
structure
4, 14
. Its anorexigenic effect requires the (central) GLP-1 receptor only
15
. Thus, 
OXM probably impacts on food intake via neural routes in the ARC, which are similarly 




 Gut-hormones are important for the regulation of glucose metabolism. We 
recently showed that ghrelin and PYY3-36 affect insulin sensitivity via mechanistic routes 
that are independent of food intake and body weight
21, 22
. Also, recent evidence suggests 
that GLP-1 ameliorates insulin resistance and hyperglycemia in diabetic ob/ob mice
23
. 
Therefore, we speculated that OXM could impact on insulin sensitivity in insulin resistant 
mice. The aim of this study was to explore the effects of systemic OXM administration on 
glucose tolerance and insulin sensitivity in diet-induced insulin resistant C57Bl/6 mice. To 
this end, we injected OXM intraperitoneally (i.p.) prior to an i.p. glucose tolerance test 
(IPGTT), and administered OXM intravenously (i.v.) during a hyperinsulinemic euglycemic 
clamp in high-fat-fed, insulin resistant C57Bl/6 mice. 
 
Methods 
Animals and diet. Male C57Bl/6 mice (12 weeks old)(Charles River, Maastricht, the 




were fed a high-fat diet (44 energy% fat derived from bovine fat, Hope Farms, Woerden, 
The Netherlands) with free access to water for 16-20 weeks to induce insulin resistance
24
. 
All animal experiments were approved by the Animal Ethics Committee from the Leiden 
University Medical Center, Leiden, The Netherlands. 
 
Drugs. OXM (human, mouse, rat; molecular weight = 4449, 90 g/mol) was purchased from 
Phoenix Pharmaceuticals (Belmont, USA). 
 
Intraperitoneal glucose tolerance test. After 16 weeks on diet, mice were fasted for 10 
hours with food withdrawn at 23:00 p.m. the day prior to the study. At 9:00 a.m. the 
experimental day, mice were given an i.p. injection of OXM dissolved in PBS (0.75, 2.5, or 
7.5 nmol) or PBS alone in a volume of 100 µl. The doses were based on a previous report 
in which OXM 0.75 nmol reduced food intake in rats
9, 10
. Fifteen minutes after injection 
blood was taken, immediately followed by i.p. injection of a 2 g/kg 20% D-glucose solution 
(t=0). Additional blood samples were taken via tail bleeding at 5, 15, 30, 45, 60, and 120 
minutes after glucose injection for measurement of plasma glucose and insulin levels. 
 
Hyperinsulinemic euglycemic clamp study. The same cohort of mice was used for the 
clamp study as for the IPGTT with 4 weeks of intermission. Mice were fasted for 16 hours 
with food withdrawn at 17:00 p.m. the day prior to the study. Hyperinsulinemic 
euglycemic clamp studies started at 9:00 a.m. and were performed as described earlier
25
. 
During the experiment, mice were sedated with 6.25 mg/kg acepromazine (Alfasan, 
Woerden, The Netherlands), 6.25 mg/kg midazolam (Roche, Mijdrecht, The Netherlands), 
and 0.3125 mg/kg fentanyl (Janssen-Cilag, Tilburg, The Netherlands). Vehicle or OXM was 
administered in a primed (0 and 0.45 nmol respectively) continuous (0 and 0.75 nmol/h 
respectively) i.v. infusion during the whole experiment. First, basal rate of glucose 
turnover was determined by giving a primed (p) continuous (c) i.v. infusion of 
14
C-glucose 
(p: 0.7 µCi; c: 1.2 µCi/h, GE Healthcare, Little Chalfont, U.K.) for 60 minutes. Subsequently, 
insulin was administered in a primed (4.5 mU) continuous (6.8 mU/h) i.v. infusion for 90 
minutes to attain steady state circulating insulin levels of ~4 ng/ml. A variable i.v. infusion 
of a 12.5% D-glucose solution was used to maintain euglycemia as determined at 10 min 
intervals via tail bleeding (< 3 µl) (Accu-chek, Sensor Comfort, Roche Diagnostics GmbH, 
Mannheim, Germany). Blood samples (60 µl) were taken during the basal period (after 50 
and 60 min) and during the clamp period (after 70, 80, and 90 min) to determine plasma 
concentrations of glucose, non-esterified fatty acids (NEFA), insulin, and plasma 
14
C-





H]DG; Amersham, Little Chalfont, UK) was 
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administered as a bolus (2 µCi) 40 minutes before the end of the clamp. At the end of the 
clamp, mice were sacrificed and skeletal muscle (hind limb) and white adipose tissue 
(abdomen) were isolated and immediately frozen in liquid nitrogen for subsequent 
analysis. 
 
Analytical procedures. Plasma levels of glucose and NEFA were determined using 
commercially available kits (Instruchemie, Delfzijl, The Netherlands). Plasma insulin 
concentrations were measured by a mouse insulin ELISA (Mercodia AB, Uppsala, Sweden). 
Total plasma 
14
C-glucose was determined in 7.5 µl plasma and in supernatants after 





Tissue analysis. For determination of tissue 2-DG uptake, the homogenate of muscle and 
adipose tissue was boiled and the supernatant was subjected to an ion-exchange column 




Calculations. Areas under the curve (AUC) for glucose (AUCglucose) and insulin (AUCinsulin) 
were calculated using the trapezoidal rule. The turnover rate of glucose (µmol/min/kg) 
was calculated during the basal period and under steady-state clamp conditions as the 
rate of tracer infusion (dpm/min) divided by the plasma-specific activity of 
14
C-glucose 
(dpm/µmol). The ratio was corrected for body weight. Endogenous glucose production 
(EGP) was calculated as the difference between the tracer-derived rate of glucose 
appearance and the glucose infusion rate. The whole body insulin sensitivity index was 
calculated as the ratio of glucose disposal to plasma insulin levels during hyperinsulinemic 
conditions. The hepatic insulin sensitivity index was calculated as the ratio of the relative 
suppression of EGP during the hyperinsulinemic condition to the change in plasma insulin 
levels from basal to hyperinsulinemic conditions. Tissue-specific glucose uptake was 
calculated from tissue 2-DG content, which was expressed as percentage of 2-DG of the 




Statistical analysis. Differences between groups were determined with the Kruskal–Wallis 
non-parametric test for k independent samples. When significant differences were found, 
the Mann–Whitney non-parametric test was used as a post hoc test to determine 
differences between two independent groups. A P-value of less than 0.05 was considered 






Glucose tolerance test 
OXM significantly improved glucose tolerance in a dose-dependent way, as evidenced by a 
reduction of the area under the curve of glucose concentrations (AUCglucose: OXM, 7.5 
nmol: 1564 ± 460, p<0.01; 2.5 nmol: 1828 ± 684, p<0.01; 0.75 nmol: 2322 ± 303, p<0.05; 
control: 2790 ± 222 mmol/l/120 min)(figure 1A and B). Insulin levels in response to 
glucose administration were significantly increased in animals receiving 7.5 nmol OXM 
compared to control animals (AUCinsulin: 343 ± 113 vs. 231 ± 39 ng/ml/120 min, 
p<0.05)(figure 2A and B), but not in animals treated with 2.5 or 0.75 nmol of OXM.  
 
 
Figure 1. Plasma glucose (A) immediately before and 5, 
15, 30, 45, 60, and 120 min after an intraperitoneal (i.p.) 
injection of glucose (2g/kg) in mice that received a single 
i.p. injection of vehicle or OXM at t=-15 (n=6/group). (B) 
Area under 120-min glucose curve. Values represent 
mean ± SD. *P<0.05 vs. control. **P<0.01 vs. control. 
Figure 2. Plasma insulin (A) immediately before and 5, 15, 
30, 45, 60, and 120 min after an intraperitoneal (i.p.) 
injection of glucose (2g/kg) in mice that received a single 
i.p. injection of vehicle or OXM at t=-15 (n=6/group). (B) 
Area under 120-min insulin curve. Values represent mean 
± SD. *P<0.05 vs. control. **P<0.01 vs. control. 
 
Hyperinsulinemic euglycemic clamp 
Plasma parameters and body weight 
Body weight, plasma glucose, insulin, and NEFA concentrations in basal and 
hyperinsulinemic conditions are shown in table 1. Basal glucose and insulin levels were 
significantly higher and basal NEFA levels significantly lower in mice that received OXM 
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compared to control mice. In hyperinsulinemic steady state clamp conditions, insulin 
levels remained significantly higher and plasma NEFA levels significantly lower in OXM 
treated mice compared to control mice.  
 
Table 1. Body weight and plasma parameters under basal and hyperinsulinemic conditions in mice that received continuous 




 Control OXM 
 
Control OXM 
Body weight, g 37.1 ± 3.2 38.4 ± 1.8 
 
  
Glucose, mmol/l 5.9 ± 0.8 13.4 ± 2.8** 
 
6.5 ± 1.0 7.1 ± 1.1 
Insulin, ng/ml 2.0 ± 1.4 14.1 ± 2.6*** 
 
4.4 ± 2.2 10.6 ± 2.8** 
NEFA, mmol/l 0.6 ± 0.2 0.2 ± 0.1** 
 
0.3 ± 0.2 0.1 ± 0.1* 
 
Values are ± means SD. OXM, oxyntomodulin; NEFA, nonesterified fatty acids. *P<0.05 vs. control. **P<0.01 vs. control. 
***P<0.001 vs. control. 
 
Glucose turnover and tissue-specific glucose uptake 
In basal conditions, EGP was significantly higher in the OXM-treated animals compared to 
control animals (82.2 ± 14.7 vs. 39.9 ± 5.7 µmol/min/kg, p<0.001). The rate of glucose 
infusion required to maintain euglycemia during insulin infusion was significantly higher in 
OXM-treated mice than in control mice (118.6 ± 30.8 vs. 38.8 ± 26.4 µl/h, respectively, 
p<0.001). This was because glucose disposal was significantly enhanced (88.1 ± 13.0 vs. 
45.2 ± 6.9 µmol/min/kg in controls, p<0.001, figure 3A) and glucose production more 
suppressed (35.7 ± 15.5 vs. 15.8 ± 11.4% inhibition in controls, P<0.05, figure 4A) during 
insulin infusion in OXM-treated animals. Accordingly, insulin-mediated 2-deoxy-glucose 
uptake in adipose and muscle tissue were significantly higher in OXM-treated mice 
(adipose tissue: 1.3 ± 0.8 vs. 0.5 ± 0.2 µmol/g tissue in controls, p<0.01; muscle: 5.2 ± 2.9 
vs. 2.2 ± 1.1 µmol/g tissue in controls, p<0.05). However, the plasma insulin 
concentrations attained by insulin infusion were significantly higher in OXM-treated mice 
compared to control (10.6 ± 2.8 vs. 4.4 ± 2.2 ng/ml, p<0.01). Therefore, we also present 
the data per unit of circulating insulin concentration. The whole body and hepatic insulin 
sensitivity indices were not different between groups (whole body insulin sensitivity index: 
8.9 ± 2.6 vs. 12.2 ± 5.2 µmol/min/kg/ng insulin/ml, NS; hepatic insulin sensitivity index: 3.5 






Figure 3. Hyperinsulinemic glucose disposal (A) and whole 
body insulin sensitivity index (B) in mice that received 
continuous intravenous infusion of vehicle (n=8) or OXM 
(n=7) during a hyperinsulinemic euglycemic clamp. Values 
represent mean ± SD. *P<0.001 vs. control. 
Figure 4. Inhibition of endogenous glucose production 
(EGP) (A) and hepatic insulin sensitivity index (B) in mice 
that received continuous intravenous infusion of vehicle 
(n=8) or OXM (n=7) during a hyperinsulinemic euglycemic 
clamp. Values represent mean ± SD. *P<0.05 vs. control. 
 
Discussion 
This is the first study to show that systemic administration of OXM beneficially affects 
glucose metabolism in diet-induced insulin resistant C57Bl/6 mice. A single i.p. injection of 
OXM dose-dependently ameliorates glucose intolerance in these animals. The plasma 
insulin concentrations in response to glucose administration were higher in OXM treated 
animals, particularly after the highest dose. In apparent contrast, i.v. OXM administration 
clearly enhanced EGP in fasted animals. During the euglycemic clamp, i.v. OXM stimulated 
glucose uptake and curtailed EGP, suggesting that it improved insulin action. However, 
circulating insulin levels were more than double during insulin infusion in OXM treated 
mice, complicating the interpretation of the data. Indeed, per unit of ambient insulin 
concentration, glucose uptake and EGP were not different in OXM and placebo treated 
animals. In aggregate, our data indicate that systemic OXM administration improves 
glucose tolerance in insulin resistant C57Bl/6 mice, primarily because it elevates plasma 
Oxyntomodulin and glucose metabolism 
29 
 
insulin levels. Minor effects on insulin action cannot be excluded. In fasting condition, 
systemic OXM injection stimulates EGP. 
 Oxyntomodulin dose-dependently improved glucose tolerance in mice 
maintained on a high fat diet. Post-load plasma glucose concentrations are the result of 
the concerted effects of insulin secretion, clearance and action on glucose metabolism. 
Insulin levels in response to glucose administration were significantly higher in OXM 
treated animals, suggesting that OXM stimulates insulin secretion and/or inhibits insulin 
clearance from the circulation. Indeed, OXM has been shown to stimulate glucose-induced 
insulin release in perfused rat pancreas
28
, which may be mediated by binding of OXM to 
the GLP-1 and/or glucagon receptor in β-cells. A unique receptor for OXM has not been 
identified to date. However, OXM was shown to bind and activate GLP-1 and glucagon 
receptors, albeit with lower affinity than the cognate ligands
4, 14
. β-cells express GLP-1 as 
well as glucagon receptors
29, 30
 and both ligands reinforce glucose-induced insulin 
secretion
31-34
. Thus, OXM most likely triggered insulin secretion by simultaneous activation 
of GLP-1 and glucagon receptors on β-cells
35
. However, interaction with (an)other 
receptor(s) cannot be excluded as OXM was shown to induce contraction of antral smooth 
muscle cells in an in vitro model in which GLP-1 and glucagon had no effect at all
36
. 
 GLP-1 retards insulin clearance from the circulation in mice
37
, which suggests that 
OXM may also slow insulin clearance to elevate glucose-induced plasma insulin levels. This 
inference is strongly supported by our finding that OXM administration more than 
doubled plasma insulin concentrations in the face of insulin infusion rates similar to those 
in placebo treated animals during the hyperinsulinemic clamp. In any case, our data clearly 
suggest that the beneficial effect of OXM on glucose tolerance is entirely due to elevation 
of post-load plasma insulin concentrations, because OXM did not significantly impact on 
insulin action as quantified by hyperinsulinemic euglycemic clamp. 
OXM inhibits food intake in rats, mice and humans
8-10
. Other gut peptides, that 
similarly decrease appetite, also modulate insulin action and glucose metabolism
21-23
. In 
fact, many peptides involved in the control of feeding simultaneously regulate 
metabolism, illustrating the intuitively obvious notion that food intake and metabolism 
share common regulatory pathways
38-40
. Therefore, we speculated that oxyntomodulin 
could also impact on insulin action. However, although OXM dose-dependently improved 
glucose tolerance, it did not appear to affect insulin action, as glucose disposal and EGP on 
a per-unit-of-circulating-insulin-concentration basis were not different in OXM versus 
placebo infused animals during the euglycemic clamp. Correction of glucose production 
and uptake rates for plasma insulin levels is rather complex, as insulin action does not 
linearly correlate with plasma insulin concentrations
41
. Thus, glucose production and 




measure of insulin’s capacity to impact on these metabolic processes. However, we 
believe it’s the best measure we have, given the fact that circulating insulin levels were 
almost twofold higher in OXM treated animals during the clamp. Therefore, we cannot 
exclude minor effects of OXM on insulin sensitivity, also in light of the data from the 
IPGTT, showing that the two lowest doses of OXM did improve glucose tolerance without 
increased insulin levels. 
The failure of OXM to deeply impact on insulin action may have to do with its 
affinities for both the GLP-1 and the glucagon receptors. Although GLP-1 and glucagon 
similarly stimulate insulin secretion, these peptides generally relay opposing metabolic 
messages. GLP-1 inhibits food intake
19
 and simultaneously improves insulin action in 
diabetic mice
23
, whereas glucagon antagonizes insulin action (it stimulates EGP and 
indirectly inhibits glucose disposal by stimulating lipolysis
42, 43
). Thus, simultaneous 
activation of both GLP-1 and glucagon receptors by systemic administration of OXM is 
unlikely to significantly impact on insulin action.  
 Our findings suggest that OXM may be the base of new pharmacological tools to 
ameliorate glucose intolerance in insulin resistant subjects. The mice examined in our 
studies were maintained on a high fat diet, which invariably induces obesity and insulin 
resistance in the C57Bl/6 strain
24
. Thus, the fact that OXM can improve glucose tolerance 
in these animals indicates that this peptide (or any novel peptidomimetic) may be useful 
in the treatment of obesity and type 2 diabetes, like other proglucagon derived peptides
44
. 
However, OXM enhanced glucose production in basal condition, probably by virtue of its 
capacity to activate the glucagon receptor in the liver
4, 45
. Obviously, stimulation of glucose 
production is an undesirable quality of drugs used to treat insulin resistance, which 
requires careful evaluation. At the end of the day, if it turns out to be a consistent 
metabolic effect of treatment with OXM (-mimetics), excessive glucose production clearly 
limits the clinical applicability of this peptide. 
 In conclusion, OXM beneficially affects glucose metabolism in diet-induced insulin 
resistant C57Bl/6 mice. It improves glucose tolerance, enhances glucose disposal by 
peripheral tissues, and reduces glucose production, primarily by elevating glucose induced 
plasma insulin levels.  
 
This study was supported by The Dutch Scientific Research Council projects 907-00-002 (to E. P. M. 









 1.  Dhanvantari S, Seidah NG, Brubaker PL. Role of prohormone convertases in the tissue-specific 
processing of proglucagon. Mol Endocrinol 1996;10:342-355. 
 2.  Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF. Preproglucagon gene expression 
in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 
1986;261:11880-11889. 
 3.  Lui EY, Asa SL, Drucker DJ, Lee YC, Brubaker PL. Glucagon and related peptides in fetal rat 
hypothalamus in vivo and in vitro. Endocrinology 1990;126:110-117. 
 4.  Bataille D, Tatemoto K, Gespach C, Jornvall H, Rosselin G, Mutt V. Isolation of glucagon-37 
(bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the 
peptide. FEBS Lett 1982;146:79-86. 
 5.  Ghatei MA, Uttenthal LO, Christofides ND, Bryant MG, Bloom SR. Molecular forms of human 
enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in 
disorders of the upper gastrointestinal tract. J Clin Endocrinol Metab 1983;57:488-495. 
 6.  Le Quellec A, Kervran A, Blache P, Ciurana AJ, Bataille D. Oxyntomodulin-like immunoreactivity: 
diurnal profile of a new potential enterogastrone. J Clin Endocrinol Metab 1992;74:1405-1409. 
 7.  Dubrasquet M, Bataille D, Gespach C. Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): a 
potent inhibitor of pentagastrin-stimulated acid secretion in rats. Biosci Rep 1982;2:391-395. 
 8.  Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, Frost GS, Ghatei MA, Bloom 
SR. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol 
Metab 2003;88:4696-4701. 
 9.  Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM, Ghatei MA, Bloom SR. Oxyntomodulin 
inhibits food intake in the rat. Endocrinology 2001;142:4244-4250. 
 10.  Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA, Bloom SR. 
Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 
2004;145:2687-2695. 
 11.  Blache P, Kervran A, Bataille D. Oxyntomodulin and glicentin: brain-gut peptides in the rat. 
Endocrinology 1988;123:2782-2787. 
 12.  Kervran A, Blache P, Bataille D. Distribution of oxyntomodulin and glucagon in the gastrointestinal 
tract and the plasma of the rat. Endocrinology 1987;121:704-713. 
 13.  Chaudhri OB, Parkinson JR, Kuo YT, Druce MR, Herlihy AH, Bell JD, Dhillo WS, Stanley SA, Ghatei 
MA, Bloom SR. Differential hypothalamic neuronal activation following peripheral injection of GLP-
1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. 
Biochem Biophys Res Commun 2006;350:298-306. 
 14.  Gros L, Thorens B, Bataille D, Kervran A. Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, 





 15.  Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 
differentially regulate murine food intake and energy expenditure. Gastroenterology 
2004;127:546-558. 
 16.  Adams SH, Won WB, Schonhoff SE, Leiter AB, Paterniti JR, Jr. Effects of peptide YY[3-36] on short-
term food intake in mice are not affected by prevailing plasma ghrelin levels. Endocrinology 
2004;145:4967-4975. 
 17.  Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, 
Ghatei MA, Cone RD, Bloom SR. Gut hormone PYY(3-36) physiologically inhibits food intake. 
Nature 2002;418:650-654. 
 18.  Challis BG, Pinnock SB, Coll AP, Carter RN, Dickson SL, O'Rahilly S. Acute effects of PYY3-36 on food 
intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 
2003;311:915-919. 
 19.  Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, 
Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR. A role for glucagon-like 
peptide-1 in the central regulation of feeding. Nature 1996;379:69-72. 
 20.  Wang L, Saint-Pierre DH, Tache Y. Peripheral ghrelin selectively increases Fos expression in 
neuropeptide Y - synthesizing neurons in mouse hypothalamic arcuate nucleus. Neurosci Lett 
2002;325:47-51. 
 21.  Heijboer AC, van den Hoek AM, Parlevliet ET, Havekes LM, Romijn JA, Pijl H, Corssmit EP. Ghrelin 
differentially affects hepatic and peripheral insulin sensitivity in mice. Diabetologia 2006;49:732-
738. 
 22.  van den Hoek AM, Heijboer AC, Corssmit EP, Voshol PJ, Romijn JA, Havekes LM, Pijl H. PYY3-36 
reinforces insulin action on glucose disposal in mice fed a high-fat diet. Diabetes 2004;53:1949-
1952. 
 23.  Lee YS, Shin S, Shigihara T, Hahm E, Liu MJ, Han J, Yoon JW, Jun HS. Glucagon-like peptide-1 gene 
therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity 
and reducing hepatic gluconeogenesis. Diabetes 2007;56:1671-1679. 
 24.  Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN. Diet-induced type II diabetes in 
C57BL/6J mice. Diabetes 1988;37:1163-1167. 
 25.  Voshol PJ, Jong MC, Dahlmans VE, Kratky D, Levak-Frank S, Zechner R, Romijn JA, Havekes LM. In 
muscle-specific lipoprotein lipase-overexpressing mice, muscle triglyceride content is increased 
without inhibition of insulin-stimulated whole-body and muscle-specific glucose uptake. Diabetes 
2001;50:2585-2590. 
 26.  Goudriaan JR, Dahlmans VE, Teusink B, Ouwens DM, Febbraio M, Maassen JA, Romijn JA, Havekes 
LM, Voshol PJ. CD36 deficiency increases insulin sensitivity in muscle, but induces insulin 
resistance in the liver in mice. J Lipid Res 2003;44:2270-2277. 
 27.  Rossetti L, Giaccari A. Relative contribution of glycogen synthesis and glycolysis to insulin-
mediated glucose uptake. A dose-response euglycemic clamp study in normal and diabetic rats. J 
Clin Invest 1990;85:1785-1792. 
Oxyntomodulin and glucose metabolism 
33 
 
 28.  Jarrousse C, Bataille D, Jeanrenaud B. A pure enteroglucagon, oxyntomodulin (glucagon 37), 
stimulates insulin release in perfused rat pancreas. Endocrinology 1984;115:102-105. 
 29.  Moens K, Heimberg H, Flamez D, Huypens P, Quartier E, Ling Z, Pipeleers D, Gremlich S, Thorens B, 
Schuit F. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-
dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 1996;45:257-261. 
 30.  Moens K, Flamez D, Van Schravendijk C, Ling Z, Pipeleers D, Schuit F. Dual glucagon recognition by 
pancreatic beta-cells via glucagon and glucagon-like peptide 1 receptors. Diabetes 1998;47:66-72. 
 31.  Holst JJ, Orskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing 
hormone from the distal gut. FEBS Lett 1987;211:169-174. 
 32.  Huypens P, Ling Z, Pipeleers D, Schuit F. Glucagon receptors on human islet cells contribute to 
glucose competence of insulin release. Diabetologia 2000;43:1012-1019. 
 33.  Kawai K, Yokota C, Ohashi S, Watanabe Y, Yamashita K. Evidence that glucagon stimulates insulin 
secretion through its own receptor in rats. Diabetologia 1995;38:274-276. 
 34.  Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous 
synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused 
at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 
1993;76:912-917. 
 35.  Dalle S, Longuet C, Costes S, Broca C, Faruque O, Fontes G, Hani EH, Bataille D. Glucagon promotes 
cAMP-response element-binding protein phosphorylation via activation of ERK1/2 in MIN6 cell line 
and isolated islets of Langerhans. J Biol Chem 2004;279:20345-20355. 
 36.  Rodier G, Magous R, Mochizuki T, Martinez J, Nguyen DL, Bali JP, Bataille D, Jarrousse C. Effect of 
glicentin, oxyntomodulin and related peptides on isolated gastric smooth muscle cells. Pflugers 
Arch 1997;434:729-734. 
 37.  Ahren B, Thomaseth K, Pacini G. Reduced insulin clearance contributes to the increased insulin 
levels after administration of glucagon-like peptide 1 in mice. Diabetologia 2005;48:2140-2146. 
 38.  Baskin DG, Figlewicz LD, Seeley RJ, Woods SC, Porte D, Jr., Schwartz MW. Insulin and leptin: dual 
adiposity signals to the brain for the regulation of food intake and body weight. Brain Res 
1999;848:114-123. 
 39.  Niswender KD, Baskin DG, Schwartz MW. Insulin and its evolving partnership with leptin in the 
hypothalamic control of energy homeostasis. Trends Endocrinol Metab 2004;15:362-369. 
 40.  Yildiz BO, Haznedaroglu IC. Rethinking leptin and insulin action: therapeutic opportunities for 
diabetes. Int J Biochem Cell Biol 2006;38:820-830. 
 41.  Bonadonna RC, Groop L, Kraemer N, Ferrannini E, Del Prato S, DeFronzo RA. Obesity and insulin 
resistance in humans: a dose-response study. Metabolism 1990;39:452-459. 
 42.  Cherrington AD, Stevenson RW, Steiner KE, Davis MA, Myers SR, Adkins BA, Abumrad NN, Williams 
PE. Insulin, glucagon, and glucose as regulators of hepatic glucose uptake and production in vivo. 




 43.  Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 
2003;284:E671-E678. 
 44.  Bond A. Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus. Proc (Bayl 
Univ Med Cent ) 2006;19:281-284. 
 45.  Baldissera FG, Holst JJ, Knuhtsen S, Hilsted L, Nielsen OV. Oxyntomodulin (glicentin-(33-69)): 
pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and 









CNTO736, a novel GLP-1 receptor agonist, ameliorates 
insulin resistance and inhibits very low density 












, Janny P. Schröder-van der Elst
1





















Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, the 
Netherlands  
2
 Centocor R&D, Inc., Discovery Research, Radnor, PA, USA  
3
 Organization of Applied Scientific Research-Prevention and Health, Gaubius Laboratory, Leiden, the 
Netherlands 
4
 Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands 
5
 Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands 
 
 





CNTO736 is a glucagon-like peptide-1 (GLP-1) receptor agonist that incorporates a GLP-1 
peptide analogue linked to the Mimetibody platform. We evaluate the potential of 
acute and chronic CNTO736 treatment on insulin sensitivity and very low density 
lipoprotein (VLDL) metabolism. For acute studies, diet-induced insulin resistant C57Bl/6 
mice received a single i.p. injection of CNTO736 or vehicle. Chronic effects were studied 
following 4 weeks daily i.p. administration. A hyperinsulinemic-euglycemic clamp 
monitored insulin sensitivity. A single dose of CNTO736 reduced fasting plasma glucose 
levels (CNTO736: 4.4 ± 1.0; control: 6.3 ± 2.4 mM) and endogenous glucose production 
(EGP) (CNTO736: 39 ± 11; control: 53 ± 13 µmol/min/kg) and increased insulin mediated 
glucose uptake (CNTO736: 76 ± 25; control: 54 ± 13 µmol/min/kg). Chronic administration 
of CNTO736 reduced fasting glucose levels (CNTO736: 4.1 ± 0.8; control 6.0 ± 1.0 mM), 
improved insulin dependent glucose uptake (CNTO736: 84 ± 19; control: 61 ± 15 
µmol/min/kg), and enhanced inhibition of EGP (CNTO736: 91 ± 18; control: 80 ± 10 % 
inhibition). In addition, chronic dosing with CNTO736 reduced fasting EGP (CNTO736: 39 ± 
9; control: 50 ± 8 µmol/min/kg) and VLDL production (CNTO736: 157 ± 23; control: 216 ± 
36 µmol/h/kg). These results indicate that CNTO736 reinforces insulin’s action on glucose 
disposal and production in diet-induced insulin resistant mice. In addition, CNTO736 
reduces basal hepatic glucose and VLDL output in these animals. The data suggest that 
CNTO736 may be a useful tool in the treatment of type 2 diabetes. 
 
 




Glucagon-like peptide 1 (GLP-1) is an incretin hormone synthesized in enteroendocrine L-
cells and brain tissue
1, 2
. It is released by the gut in response to food intake to stimulate 
glucose-induced insulin production
1, 3
. In addition, GLP-1 exerts multiple other effects, 
including inhibition of food intake, slowing of gastric emptying and inhibition of glucagon 
secretion
4, 5
. Some, but certainly not all, studies suggest that GLP-1 secretion in response 
to meals is reduced in patients with type 2 diabetes mellitus (T2DM)
6-8
, which attenuates 
postprandial insulin release and potentially blunts satiety. Continuous infusion of GLP-1 
lowers circulating glucose levels after ingestion of a meal and normalizes fasting 
hyperglycemia in these patients
5, 9
. Native GLP-1 is not an appropriate candidate molecule 
for therapeutic intervention, because of its rapid degradation by dipeptidyl-peptidase-4 
(DPP-4)
10
. However, GLP-1 analogues with extended in vivo stability are currently under 
development by many pharmaceutical companies.  Byetta (exendin-4 (Ex-4)) was 
approved in 2005 to treat T2DM
11
. 
We have developed the Mimetibody platform for display and delivery of 
bioactive peptides
12
. Mimetibodies have longer terminal half-lives relative to peptides 
due to their increased size and antibody Fc properties. CNTO736 incorporates a DPP-4 
resistant GLP-1 peptide analogue into the Mimetibody platform. Despite these physical 
adaptations, it retains GLP-1-like biological activity: it stimulates glucose-dependent 
insulin secretion, inhibits food intake and gastric emptying, and improves glucose 
tolerance in diet-induced obese mice in a GLP-1 receptor dependent manner
13
. 
 Here, we further explore the pharmacological characteristics of CNTO736 in 
terms of its metabolic effects. In particular we evaluate the acute and chronic impact of 
the compound on insulin sensitivity of glucose and lipid metabolism. Overproduction of 
very low density lipoprotein (VLDL), which is a prominent feature of diabetic dyslipidemia 
(as the proximate cause of hypertriglyceridemia), contributes significantly to 
cardiovascular risk in T2DM patients
14
. A few studies show that GLP-1 treatment and DPP-
4 inhibition reduce circulating triglyceride (TG) levels in healthy humans and T2DM 





Animals and diet. Male C57Bl/6 mice (12 weeks old) (Charles River, Maastricht, the 
Netherlands) were housed in a temperature and humidity-controlled environment and 
were fed a high-fat diet (44 energy% fat derived from bovine fat, Hope Farms, Woerden, 






animal experiments were approved by the Animal Ethics Committee from the Leiden 
University Medical Center, Leiden, The Netherlands. 
  
Expression and Purification of CNTO736. CNTO736 was constructed by fusing a GLP-1 
peptide analogue to a flexible Gly/Ser linker and a fragment of a VH domain linked directly 
to the CH2 and CH3 domains of an Fc
13
. A gene encoding CNTO736 was cloned into a 
vector for mammalian expression under control of the CMV promoter. For transient 
expression, HEK 293E cells were expanded (DMEM (Invitrogen, Carlsbad, CA, USA) + 10% 
FBS) and used to seed a 10-tier cell factory (5 x 10
7
 cells in growth medium (1200 ml)). 24 
h after seeding, the cells were transfected. 24 h later, the growth medium/transfection 
mix was removed and replaced with 293-SFMII medium (Invitrogen, Carlsbad, CA, USA) 
supplemented with 5 mmol/l sodium butyrate (1200 ml). Four days later, the conditioned 
medium was harvested, filtered, and stored at 4
o
C until purification. CNTO736 was 
purified using a Protein A MabSelect column (GE Healthcare, Piscataway, NJ, USA) and 
Immunopure Gentle Ag/Ab binding and elution buffers (Pierce, Rockland, IL, USA). The 
purified product was dialyzed into 20 mmol/l Tris, pH 7.4 prior to concentration. The final 
column was a Superdex 200 column (GE Healthcare, Piscataway, NJ, USA) in phosphate 
buffered saline (PBS). Selected fractions were pooled and concentrated. 
 
Treatments. Mice enrolled in the acute study of CNTO736 and Ex-4 (generic name: 
exenatide) were divided into 4 groups. Each group received a single i.p. injection of 
CNTO736 (0.1 or 1.0 mg/kg, dissolved in PBS), Ex-4 (7.1 µg/kg, dissolved in PBS. This dose 
of Ex-4 is on a molar base equivalent to 0.1 mg/kg CNTO736) (Sigma-Aldrich, Zwijndrecht, 
The Netherlands), or PBS in a volume of 100 µl at 08.00 a.m. at the end of the 10 week 
high-fat diet period. The clamp studies began exactly 1 h later. Mice enrolled in the 
chronic study of CNTO736 and Ex-4 were matched for body weight and fasting plasma 
glucose concentration after 6 weeks of high-fat-feeding, where after they were divided 
into 4 groups. Each group received daily i.p. doses of CNTO736 (0.1 or 1.0 mg/kg), Ex-4 
(7.1 µg/kg), or PBS in a volume of 100 µl at 08.00 a.m. during the remaining 4 weeks on 
diet. At 08.00 a.m. on the last day of the 10 week high-fat diet period, animals were given 
a last i.p. dose and the clamp studies were initiated 1 h later. 
 
Hyperinsulinemic-euglycemic clamp study. Mice were fasted for 10 h with food 
withdrawn at 23:00 p.m. the day prior to the start of the study. Hyperinsulinemic-
euglycemic clamps started 1 h after the last dose. During the experiment, mice were 
sedated with 6.25 mg/kg acepromazine (Alfasan, Woerden, The Netherlands), 6.25 mg/kg 
midazolam (Roche, Mijdrecht, The Netherlands), and 0.3125 mg/kg fentanyl (Janssen-
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Cilag, Tilburg, The Netherlands). First, basal rates of glucose and glycerol turnover were 
determined by giving a primed (p) continuous (c) i.v. infusion of D-[U-
14
C]Glucose (p: 0.2 
µCi; c: 0.3 µCi/h, GE Healthcare, Little Chalfont, U.K.) and [1-(3)-
3
H]Glycerol (p: 0.6 µCi; c: 
0.9 µCi/h, GE Healthcare) for 60 min. Subsequently, insulin was administered in a primed 
(4.5 mU) continuous (6.8 mU/h) i.v. infusion for 90 min to attain steady state circulating 
insulin levels of ~4 ng/ml. A variable i.v. infusion of a 12.5% D-glucose solution was used 
to maintain euglycemia as determined at 10 min intervals via tail bleeding (< 3 µl) (Accu-
chek, Sensor Comfort, Roche Diagnostics GmbH, Mannheim, Germany). Blood samples (60 
µl) were taken via tail bleeding during the basal period (after 50 and 60 min) and during 
the clamp period (after 70, 80, and 90 min) to determine plasma concentrations of 





specific activities. At the end of the clamp, mice were used to determine VLDL-production. 
 
VLDL production. VLDL production was determined in basal conditions (1h after the last 
treatment) and in hyperinsulinemic conditions (after the clamp experiment) in parallel 
experiments. Mice were fasted for 10h with food withdrawn at 23:00 p.m. the day prior to 
the start of the study. During the experiment, mice were sedated with 6.25 mg/kg 
acepromazine (Alfasan), 6.25 mg/kg midazolam (Roche), and 0.3125 mg/kg fentanyl 
(Janssen-Cilag). At t=0 min blood was taken via tail bleeding and mice were i.v. injected 
with 500 mg of tyloxapol (Triton WR-1339, Sigma-Aldrich) per kg body weight as a 10% 
(w/w) solution in sterile saline, which completely blocks VLDL clearance from serum
19
. 
Additional blood samples were taken at t=10, 20, 40, and 60 min after tyloxapol injection 
and used for determination of plasma TG concentration. Plasma TG concentrations were 
related to body weight and hepatic VLDL-TG production rates were calculated from the 
linear increase in TG in time and expressed as µmol/h/kg. After the last sampling mice 
were sacrificed by cervical dislocation and livers were immediately removed from the 
mice and snap-frozen in liquid nitrogen for determination of hepatic TG content. 
 
Analytical procedures. Plasma levels of glucose, NEFA, TG, and glycerol were determined 
using commercially available kits (Instruchemie, Delfzijl, The Netherlands). Plasma insulin 
(Mercodia AB, Uppsala, Sweden) and glucagon (Alpco, Salem, NH, USA) concentrations 
were measured by ELISA. Due to limited plasma, samples were pooled for glucagon 




H-glycerol were determined in 7.5 µl 
plasma and in supernatants after trichloroacetic acid (20%) precipitation and water 





Hepatic TG content. A small piece of liver was homogenated in 400 µl PBS and 1.5 ml 
CH3OH:CHCl3 (2:1, v/v) was added. After centrifugation, TG was extracted from the 
supernatant with CHCl3 and H2O (1:1, v/v) and the CHCl3 phase was dried. TG was 
dissolved in H2O with 2% Triton-X100 (Sigma). TG levels were assayed as described above.  
 
Calculations. The turnover rates of glucose and glycerol (µmol/min/kg) were calculated 
during the basal period and under steady-state clamp conditions as the rate of tracer 




H]Glycerol (dpm/µmol). The ratio was corrected for body weight. Endogenous glucose 
production (EGP) was calculated as the difference between the tracer-derived rate of 
glucose appearance and the glucose infusion rate. All metabolic parameters were 
expressed per kg of body weight. 
 
Statistical analysis. Differences between groups were determined with the Kruskal–Wallis 
non-parametric test for k independent samples. When significant differences were found, 
the 
Mann–Whitney non-parametric test was used as a follow-up test to determine differences 
between two independent groups. A p-value of less than 0.05 was considered statistically 
significant. Data are presented as mean ± SD. 
 
Results 
Plasma metabolites and body weight. Body weight, plasma glucose, NEFA, insulin, 
glucagon, and glycerol before chronic treatment and in basal and hyperinsulinemic 
conditions after acute and chronic treatment are shown in table 1.  
 
Acute effects of a single injection 
The fasting plasma glucose concentration was significantly reduced by a single 
dose of CNTO736 (1.0 mg/kg). Similarly, Ex-4 and a lower dose of CNTO736 (0.1 mg/kg) 
decreased fasting blood glucose, although the difference did not reach statistical 
significance. Other fasting metabolite concentrations (NEFA, insulin, glucagon, and 
glycerol) were not affected by any single injection.  
In the hyperinsulinemic state, insulin levels were slightly, but significantly 
elevated after a single dose of Ex-4 compared to control mice, although insulin infusion 
rates were identical and glucose concentrations were clamped at a similar level in all 
groups. Perhaps as a result, plasma NEFA concentrations were slightly more suppressed in 
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response to insulin infusion in mice treated with Ex-4 compared to control, whereas 
CNTO736 did not affect circulating NEFA levels during hyperinsulinemia. 
 
Effects of 4 weeks of daily injections 
Chronic administration of both drugs significantly reduced the fasting plasma 
glucose concentration compared to baseline values, while glucose levels remained high in 
the control group. The other plasma parameters did not differ between groups. 
In the steady state clamp condition, insulin and glucose concentrations were 
similar in all groups and hyperinsulinemia suppressed NEFA levels to a similar extent in all 
groups. Body weight was significantly reduced by chronic administration of the highest 
dose of CNTO736 only. 
 
Table 1. Plasma parameters in mice before chronic treatment and in basal or hyperinsulinemic conditions after a single or chronic 
i.p. injection of CNTO736, exendin-4 (Ex-4), or vehicle.  
   Acute Study   Chronic Study 
   Control  Ex-4  CNTO736   Control   Ex-4   CNTO736 
     0.1 mg/kg  1.0 mg/kg     0.1 mg/kg   1.0 mg/kg 
Body weight (g) 
Start treatment  -  -  -  -   26.7 ± 1.2   27.0 ± 1.9   26.6 ± 1.7   26.8 ± 1.4 
10 wks diet/ after 
treatment  30.9 ± 2.4  31.4 ± 0.9  31.3 ± 1.6  31.2 ± 2.2   27.3 ± 1.8   26.3 ± 2.0   26.1 ± 1.9   25.1 ± 1.3†† 
 Start treatment  -  -  -  -   6.5 ± 0.8   6.8 ± 0.8   6.7 ± 1.1   6.6 ± 1.4 
Glucose (mM) Basal  6.3 ± 2.4  4.6 ± 1.1  5.5 ± 1.2  4.4 ± 1.0*   6.0 ± 1.0   4.9 ± 1.1††   4.3 ± 1.0††   4.1 ± 0.8†† 
 Hyperinsulinemic  7.3 ± 1.0  7.7 ± 0.9  7.3 ± 0.5  8.0 ± 0.8   6.9 ± 0.9   7.3 ± 0.9   7.6 ± 1.1   7.6 ± 0.9 
 Start treatment  -  -  -  -   0.9 ± 0.2   0.9 ± 0.2   1.0 ± 0.1   1.0 ± 0.2 
NEFA (mM) Basal  1.3 ± 0.6  1.0 ± 0.2  1.1 ± 0.5  1.1 ± 0.5   1.1 ± 0.3   1.0 ± 0.3   1.1 ± 0.3   1.1 ± 0.2 
 Hyperinsulinemic  0.7 ± 0.3  0.5 ± 0.2*  0.7 ± 0.3  0.6 ± 0.4   0.5 ± 0.2   0.4 ± 0.1   0.5 ± 0.1   0.4 ± 0.1 
 Start treatment  -  -  -  -   1.1 ± 0.4   1.0 ± 0.5   1.0 ± 0.5   1.1 ± 0.4 
Insulin (ng/ml) Basal  1.1 ± 0.8  0.7 ± 0.5  1.1 ± 0.8  0.9 ± 0.6   1.0 ± 0.7   1.4 ± 0.7   1.1 ± 0.6   1.4 ± 1.3 
 Hyperinsulinemic  3.1 ± 1.1  4.4 ± 0.8*  3.5 ± 1.3  4.5 ± 1.7   5.4 ± 2.4   4.4 ± 0.9   4.6 ± 1.0   5.0 ± 1.9 
 Start treatment  -   -   -  -   491   502   551   580 
Glucagon (pg/ml) Basal  556  513  455  592   565   787   699   675 
 Hyperinsulinemic  569  509  476  670   575   631   580   632 
 Start treatment  -  -  -  -   0.2 ± 0.1   0.2 ± 0.1   0.2 ± 0.1   0.2 ± 0.0 
Glycerol (mM) Basal  0.2 ± 0.1  0.2 ± 0.1  0.2 ± 0.1  0.2 ± 0.1   0.2 ± 0.0   0.2 ± 0.1   0.2 ± 0.0   0.2 ± 0.1 
 Hyperinsulinemic  0.1 ± 0.1  0.1 ± 0.1  0.1 ± 0.1  0.1 ± 0.1   0.2 ± 0.1   0.1 ± 0.1   0.1 ± 0.1   0.1 ± 0.1 
 
Values represent mean ± SD for at least 8 mice per group. *p<0.05 vs control. 
††








Acute effects of a single injection 
A single dose of CNTO736 (1.0 mg/kg) inhibited endogenous glucose production 
(EGP) in the basal condition. Ex-4 reduced EGP to a similar extent, but the difference with 
control did not reach statistical significance. The lowest dose of CNTO736 (0.1 mg/kg) did 
not affect glucose metabolism in basal conditions (control: 53 ± 13; Ex-4: 40 ± 11; 0.1 
mg/kg CNTO736: 47 ± 10; 1.0 mg/kg CNTO736: 39 ± 11 µmol/min/kg, p<0.05; figure 1). 
 The high dose of CNTO736 (1.0 mg/kg) and Ex-4 significantly increased the rate 
of glucose infusion necessary to maintain euglycemia during the insulin infusion relative 
to the control (control: 52 ± 14; Ex-4: 75 ± 13, p<0.05; 0.1 mg/kg CNTO736: 63 ± 24; 1.0 
mg/kg CNTO736: 75 ± 16 µmol/min/kg, p<0.05; figure 2). This was largely because both 
drugs enhanced the ability of insulin to stimulate glucose uptake (control: 54 ± 13; Ex-4: 
72 ± 17, p<0.05; 0.1 mg/kg CNTO736: 69 ± 20; 1.0 mg/kg CNTO736: 76 ± 25 µmol/min/kg, 
p<0.05). In contrast, neither drug acutely affected insulin’s inhibitory action on EGP 
(control: 89 ± 12; Ex-4: 90 ± 14; 0.1 mg/kg CNTO736: 84 ± 14; 1.0 mg/kg CNTO736: 79 ± 19 
% from basal; figure 4). The lowest dose of CNTO736 did not affect insulin action in this 
experimental context. 
 
Effects of 4 weeks of daily injections 
Chronic dosing of CNTO736 (1.0 and 0.1 mg/kg) significantly inhibited EGP in 
basal condition. In contrast, Ex-4 did not affect EGP in the fasting condition (control: 50 ± 
8; Ex-4: 51 ± 18; 0.1 mg/kg CNTO736: 35 ± 9, p<0.05; 1.0 mg/kg CNTO736: 39 ± 9 
µmol/min/kg, p<0.05; figure 1). 
 Chronic administration of CNTO736 and Ex-4 increased the rate of glucose 
infusion necessary to maintain euglycemia during insulin infusion ((control: 47 ± 18; Ex-4: 
88 ± 16, p<0.05; 0.1 mg/kg CNTO736: 80 ± 12, p<0.05; 1.0 mg/kg CNTO736: 89 ± 16 
µmol/min/kg, p<0.05; figure 2). Chronic administration of both 1.0 mg/kg CNTO736 and 
Ex-4 enhanced insulin stimulated glucose disposal relative to control (CNTO736: 84 ± 19; 
Ex-4: 83 ± 19; control: 61 ± 15 µmol/min/kg). The lowest dose of CNTO736 (0.1 mg/kg) did 
not significantly affect glucose uptake during hyperinsulinemia relative to the control 
(CNTO736: 74 ± 15; control: 61 ± 15 µmol/min/kg). However, if expressed as percentage 
increase of baseline values, 0.1 mg/kg CNTO736 significantly increased glucose disposal 
during hyperinsulinemia (control: 30 ± 36; Ex-4: 76 ± 49, p<0.05; 0.1 mg/kg CNTO736: 125 
± 69, p<0.01; 1.0 mg/kg CNTO736: 132 ± 77 % from basal, p<0.01; figure 3). All chronic 
interventions significantly reinforced insulin’s capacity to inhibit EGP (control: 80 ± 10; Ex-
4: 98 ± 4, p<0.05; 0.1 mg/kg CNTO736: 95 ± 10, p<0.05; 1.0 mg/kg CNTO736: 91 ± 18 % 
from basal, p<0.05; figure 4).  




Figure 1. Basal endogenous glucose production (EGP) in mice that received acute or chronic i.p. injection of CNTO736, exendin-4, 
or vehicle during a hyperinsulinemic euglycemic clamp. Values represent mean ± SD for at least 8 mice per group. *p <0.05 vs 
control. **p < 0.01 vs control 
 
 
Figure 2. Glucose infusion rate (GIR) in mice that received acute or chronic i.p. injection of CNTO736, exendin-4, or vehicle during 
a hyperinsulinemic euglycemic clamp. Values represent mean ± SD for at least 8 mice per group. *p <0.05 vs control. 
 
 
Figure 3. Stimulation of glucose disposal by insulin in mice that received acute or chronic i.p. injection of CNTO736, exendin-4, or 
vehicle during a hyperinsulinemic euglycemic clamp. Values represent mean ± SD for at least 8 mice per group. *p <0.05 vs 





Figure 4. Inhibition of endogenous glucose production (EGP) by insulin in mice that received acute or chronic i.p. injection of 
CNTO736, exendin-4, or vehicle during a hyperinsulinemic euglycemic clamp. Values represent mean ± SD for at least 8 mice per 
group. **p <0.01 vs control. 
 
 
Glycerol turnover  
Acute effects of a single injection 
Basal rates of glycerol turnover were not different after a single dose of 
CNTO736, Ex-4, or vehicle. None of the treatments affected insulin’s ability to inhibit 
glycerol turnover (figure 5).  
 
 
Effects of 4 weeks of daily injections 
Chronic administration of CNTO736 and Ex-4 did not affect glycerol turnover in 
basal conditions. Hyperinsulinemia suppressed glycerol turnover to a similar extent in all 
groups (figure 5). 
 
Figure 5. Glycerol turnover in mice that received acute or chronic i.p. injection of CNTO736, exendin-4, or vehicle before (basal) 
and after (hyperinsulinemic) the initiation of a hyperinsulinemic euglycemic clamp. Values represent mean ± SD for at least 8 
mice per group. *p <0.05 vs basal. 
 





Acute effects of a single injection  
VLDL production after one single injection was similar in all groups both in basal 
and hyperinsulinemic conditions (table 2).  
 
Table 2. Body weight, plasma TG levels and VLDL production rate under basal or hyperinsulinemic conditions in mice that 
received a single or chronic i.p. injection of CNTO736 (0.1 or 1.0 mg/kg), exendin-4 (Ex-4), or vehicle.  
 
 Acute Study Chronic Study 
 
 Control    Ex-4 CNTO736 Control     Ex-4 CNTO736 
 
   0.1 mg/kg 1.0 mg/kg 
 
 0.1 mg/kg 1.0 mg/kg 
Body weight (g) 
Start treatment - -  - - 
 
  27.0 ± 1.1 
 
  27.2 ± 1.7 
 
  27.3 ±1.8 
 
  26.8 ± 1.3 
10 wks diet/ 
end treatment 
31.6 ± 2.5 31.4 ± 1.9  31.5 ± 1.8   31.5 ± 2.5   27.5 ± 1.6   26.6 ±1.8   26.6 ± 1.8   25.2 ± 1.2†† 
TG (mM) 
Start treatment - -  - -   0.79 ± 0.3   0.77 ± 0.2   0.78 ± 0.2   0.81 ± 0.3 
10 wks diet/ 
end treatment 
0.39 ± 0.1 0.35 ± 0.1  0.34 ± 0.1   0.39 ± 0.1   0.56 ± 0.2††   0.52 ± 0.1††   0.53 ± 0.1††   0.52 ± 0.1†† 
VLDL production rate Basal 229 ± 61 237 ± 16  205 ± 34   220 ± 48   216 ± 36   212 ± 55   160 ± 30*   157 ± 23* 
(µmol/h/kg) Hyperinsulinemic 190 ± 45 202 ± 47  196 ± 45   186 ± 32   176 ± 51   179 ± 40   117 ± 37*   111 ± 32* 
 
Values represent mean ± SD for at least 8 mice per group. *p <0.05 vs control and exendin-4. 
††
p <0.01 vs start treatment. 
 
Effects of 4 weeks of daily injections 
Chronic treatment decreased plasma TG levels to a similar extent in all groups 
compared to baseline values (table 2). Chronic administration of CNTO736 (0.1 and 1.0 
mg/kg) led to a significant decrease in VLDL production both in basal and in 
hyperinsulinemic conditions, whereas chronic Ex-4 treatment did not affect VLDL 
production (table 2 and figure 5). 
 
Figure 6. VLDL production rate in mice that received chronic i.p. administration of CNTO736, exendin-4, or vehicle in basal (a) or 
hyperinsulinemic (b) conditions. white squares = control; black squares = exendin-4; white circles = CNTO736 (0.1 mg/kg); black 
circles = CNTO736 (1.0 mg/kg). Values represent mean ± SD for at least 9 mice per group. 
†
p <0.05 vs control and vs exendin-4. 
**p <0.05 vs control. *
†





Hepatic TG content 
 Hepatic TG content did not differ between groups (control: 118 ± 10; Ex-4: 112 ± 
14; 0.1 mg/kg CNTO736: 113 ± 27; 1.0 mg/kg CNTO736: 120 ± 29 µg TG/ mg protein). 
 
Discussion 
Here we show that CNTO736, a novel GLP-1 receptor agonist, beneficially affects glucose 
and VLDL metabolism in diet-induced insulin resistant C57Bl/6 mice. In particular, a single 
injection of the highest dose of CNTO736 (1.0 mg/kg) acutely reduced fasting plasma 
glucose concentration and inhibited basal endogenous glucose production (EGP). 
Moreover, the capacity of insulin to stimulate glucose disposal was acutely reinforced by 
CNTO736. Chronic administration also clearly reduced plasma glucose levels and EGP 
during the fasting state and reinforced insulin’s action on glucose disposal and production. 
Moreover, chronic treatment with CNTO736 significantly inhibited VLDL production. Ex-4 
had a similar impact on glucose disposal and production in the hyperinsulinemic state, 
indicating that these effects are likely attributable to common GLP-1-like actions of the 
compounds. However, chronic Ex-4 treatment did not affect basal EGP or VLDL 
production, suggesting that CNTO736 and Ex-4 differentially act to modulate metabolism. 
The half-life of CNTO736 (15-20 h) in mice is considerably longer than that of Ex-4 (~2 h)
13
. 
At this time, we do not know whether the difference between Ex-4 and CNTO736 on 
fasting EGP and VLDL production is due to sustained exposure of CNTO736 because of its 
longer plasma half-life or due to some other unique characteristic that is specific to 
CNTO736. However, Ex-4 and CNTO736 stimulated glucose disposal and inhibited glucose 
production in hyperinsulinemic conditions to a similar degree, which suggests that 
compound kinetics cannot fully explain the CNTO736-specific effect on fasting EGP and 
VLDL production.       
 The data corroborate earlier reports indicating that GLP-1 and its analogues in 
the long run ameliorate whole body insulin resistance in obese animal models
20-22
 and in 
T2DM patients
23
. They further extend our knowledge of the precise actions of GLP-1 
analogues on distinct components of glucose flux in insulin resistant animals, inasmuch as 
they show that these compounds acutely reinforce insulin’s ability to promote glucose 
disposal and boost insulin action on both glucose uptake and production in the long term. 
Interestingly, the data also clearly show that CNTO736 inhibits VLDL production both 
in the fasting state and during hyperinsulinemia, whereas Ex-4 does not. To our 
knowledge, this is the first report of a GLP-1 analogue affecting VLDL synthesis. Native 
GLP-1 reduces postprandial plasma triglyceride levels in healthy, normal-weight humans 
and T2DM patients, and vildagliptin, a DPP-4 inhibitor that increases plasma GLP-1 levels, 
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lowers the postprandial concentration of triglyceride-rich chylomicron particles in type 2 
diabetic patients
15-17
. T2DM is a complex metabolic disorder, frequently marked by more 
anomalies than hyperglycemia alone. Overproduction of VLDL by the liver is the 
proximate cause of hypertriglyceridemia in patients with T2DM
14
, and 
hypertriglyceridemia contributes significantly to cardiovascular risk
24
. Thus, the capacity 
to inhibit VLDL production is a favorable quality of drugs designed to treat T2DM.  
The mechanisms underlying the beneficial impact of GLP-1 analogues on glucose 
metabolism remain to be established. They facilitate glucose induced insulin release by 
beta cells of course, which dampens postprandial hyperglycemia and thereby ameliorates 
glucose toxicity. The effects of chronic administration of both CNTO736 and Ex-4 on 
glucose disposal and production are conceivably at least in part attributable to this 
feature of the drugs. However, the impact of a single drug dose on glucose metabolism 
clearly indicates that other, direct mechanisms are involved.  CNTO736 and Ex-4 may act 
on peripheral tissues directly via the GLP-1 receptor (GLP-1R). However, it is unclear if the 
liver expresses GLP-1R, since there is conflicting data
25, 26
. CNTO736 and Ex-4 may 
reinforce insulin’s action via neural routes that have recently emerged as key players in 
the control of glucose and lipid metabolism
27
. GLP-1 receptors that mediate its 
anorexigenic action are expressed in multiple hypothalamic nuclei and peripheral dosing 
of CNTO736 could have allowed the molecule to reach the hypothalamus
13
. One 
possibility is that CNTO736 and Ex-4 in the hypothalamus modulate the NPY pathway. It 
has been shown previously that intracerebroventricular (i.c.v.) administration of GLP-1 
completely prevents the orexigenic effects of neuropeptide Y (NPY), which suggests that 
GLP-1 acts by blocking NPY transmission to inhibit food consumption
28
. I.c.v. 
administration of NPY acutely impairs insulin's ability to suppress EGP
29
. Also, animal 
models of obesity and type 2 diabetes (including diet-induced obesity) are marked by 
elevated NPY expression in hypothalamic nuclei
30, 31
. For these reasons, it is conceivable 
that these exceedingly active NPY neurons are involved in the pathophysiology of 
enhanced EGP in the face of hyperinsulinemia in these models (and obese humans). 
Peptide YY3-36, which inhibits NPY release in the arcuate nucleus, enhances insulin 
sensitivity in the same experimental context
32
. Therefore, chronic administration of 
CNTO736 may have antagonized NPY-induced insulin resistance to explain the findings 
presented here.  
Alternatively, CNTO736 and Ex-4 may activate neurons in the nucleus of the solitary 
tract (NTS) in the brain stem via afferent vagal inputs to modulate glucose metabolism. 
GLP-1 evokes vagal afferent nerve activity to initiate a hepato-pancreatic reflex that is 
critically involved in the control of insulin release
33
. It is conceivable, that vagal afferent 




organs as well to modulate glucose production. Moreover, in addition to its direct effects 
on hypothalamic neurons, GLP-1 conveys its message to the hypothalamus via the vagus 
nerve and the NTS
34
. Indeed, vagal ablation attenuates the anorexigenic effects of 
peripheral GLP-1 administration
34
. In analogy, activation of vagal afferents by GLP-1 may 
impact on glucose metabolism via the hypothalamus. Finally, it remains possible that GLP-
1 acts on the liver and other peripheral tissues via a structurally and functionally distinct 
GLP-1R. Indeed, GLP-1 was reported to have insulin-like actions in liver and skeletal 
muscle which are not mediated by the classical GLP-1R
35, 36
.  
Chronic administration of CNTO736 clearly inhibited VLDL production in basal and 
hyperinsulinemic conditions. The assembly of VLDL particles in the endoplasmatic 
reticulum of hepatocytes is dependent on the intracellular presence of triglycerides, other 
lipids, and apolipoprotein B (apoB) as its major components. Correct apoB lipidation and 
translocation probably limit the rate of VLDL secretion
37
. Thus, the supply of NEFA, 
released by lipolysis of circulating and stored triglycerides, to the liver is a major 
determinant of VLDL production
38
. However, CNTO736 did not affect lipolysis or insulin’s 
capacity to suppress this process and, accordingly, it did not change plasma NEFA 
concentrations. Moreover, chronic CNTO736 treatment did not impact on liver TG 
content. Therefore, CNTO736 does not appear to inhibit VLDL production via reduction of 
triglyceride lipolysis and diminution of NEFA supply to the liver.  
CNTO736 may affect liver function via one of the mechanisms discussed above. ICV 
administration of NPY acutely impairs the capacity of insulin to inhibit VLDL production
29
. 
This observation suggests that neural mechanisms are involved in the control of VLDL 
metabolism. Thus, in analogy with hypotheses pertaining to the effect of CNTO736 on 
glucose metabolism discussed above, CNTO736 may modulate VLDL release via neural 
routes that involve the hypothalamus, brain stem, and vagal nerve.  It is unclear why 
chronic treatment with Ex-4 did not result in similar effects on basal EGP and VLDL 
production. In this context, it is interesting to note that Ex-4 may have less affinity for the 
vagal GLP-1R than GLP-1 itself
39
. It is tempting to speculate, that this explains the 
difference in effect of chronic treatment with CNTO736 and Ex-4 on EGP and VLDL 
production.  
The pathophysiological consequence of the capacity of CNTO736 to inhibit VLDL 
secretion is uncertain, since circulating TG levels were not affected. It is also important to 
note, that the beneficial impact of CNTO736 on VLDL production is not simply due to a 
reduction of body weight, since a robust effect was also evident after chronic treatment 
with the lowest dose of the drug, which did not impact on body weight. 
 The current study suggests that CNTO736 has properties to provide better 
metabolic control in patients with T2DM. Chronic administration of the drug clearly 
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reinforces insulin action on glucose disposal and production in insulin resistant mice. 
Moreover, chronic CNTO736 treatment inhibits fasting EGP and VLDL synthesis in the 
same experimental context. Administration of Ex-4 has similar effects on insulin mediated 
glucose metabolism, suggesting that common, GLP-1-like effects of these compounds 
underlie their glucoregulatory action. In contrast, Ex-4 treatment did not impact fasting 
EGP and VLDL production. This could imply that CNTO736 has a unique property that is 
responsible for inhibiting glucose production and VLDL release. We speculate that 
CNTO736 acts via GLP-1 receptors on vagal afferents and hypothalamic neurons to 
modulate glucose and VLDL metabolism. 
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GLP-1 Mimetibody (GLP-1M) is a glucagon-like peptide-1 (GLP-1) receptor agonist that 
incorporates a GLP-1 peptide analogue linked to the Mimetibody platform, which has 
been shown to inhibit VLDL triglyceride production. In the present study, we further 
evaluate the potential of this compound to modulate lipid metabolism. High-fat-fed 
APOE*3-Leiden transgenic mice were administered daily i.p. injections of GLP-1M or 
placebo for 4 weeks. Plasma cholesterol concentrations, lipoprotein profiles, VLDL-TG and 
VLDL-[
35
S]apoB production rates and expression of genes involved in hepatic lipid 
metabolism were determined. GLP-1M lowered total plasma cholesterol levels (GLP-1M: 
3.7 ± 0.6; Control: 4.6 ± 0.7 mM, P<0.05) and lipoprotein fractionation showed increased 
cholesterol levels in the HDL fraction. Moreover, GLP-1M decreased the production rate of 











 dpm/ml/h, P<0.05). Finally, GLP-1M 
decreased the hepatic expression of apob (-36%, P<0.05 vs. control). In conclusion, these 
results indicate that GLP-1M improves VLDL metabolism in high-fat-fed APOE*3-Leiden 
mice and suggest the potential to ameliorate dyslipidemia in patients with type 2 
diabetes. 




Glucagon-like peptide-1 (GLP-1), an incretin hormone released by the gut in response to 
meals, stimulates insulin release, inhibits glucagon secretion, slows gastric emptying, and 
induces satiety
1-5
. Although these features hold promise for the treatment of type 2 
diabetes mellitus, native GLP-1 cannot be used as a drug because of its short plasma half-
life (several minutes). GLP-1 analogues that are resistant to hydrolysis by dipeptidyl 
peptidase IV (DPP-IV) have been developed to circumvent this problem
6
. Indeed, clinical 
studies show that they effectively improve glucose metabolism in T2DM patients
7, 8
 and 
several compounds are currently on the verge of marketing as tools to treat the disease. 
Byetta (exendin-4 (Ex-4)) was approved in this context in 2005
9, 10
. 
 Lipid metabolism is also disturbed in patients with T2DM. Increased very low 
density lipoprotein triglyceride (VLDL-TG) concentrations and decreased high-density 
lipoprotein (HDL) cholesterol in plasma significantly contribute to the long term risk of 
macrovascular disease in these patients
11, 12
. We have recently shown that chronic 
treatment with the GLP-1 receptor agonist, CNTO736, apart from its glycemic effects, 
inhibits VLDL-TG production by the liver in C57Bl/6 mice maintained on a high fat diet
13
. 
Interestingly, Ex-4 did not impact on VLDL-TG production in this insulin resistant mouse 
model, despite the fact that both Ex-4 and CNTO736 equally and profoundly ameliorated 
glycemic control. Therefore, CNTO736 may have compound-specific effects on VLDL 
metabolism that potentially reinforce its capacity to prevent macrovascular disease in high 
fat-fed mice (and humans). However, several issues need to be clarified before firm 
conclusions can be drawn with respect to the potential of the drug to modify VLDL-TG 
metabolism and, thereby, reduce macrovascular risk.  
 The objective of this study was to further explore the inhibitory effect of 
CNTO736 on VLDL-TG production. We set out to compare the chronic effects of CNTO736 
with the latest version of the molecule, from now on referred to as GLP-1 Mimetibody 
follow-up molecule (GLP-1M), and Ex-4 on lipid metabolism in APOE*3-Leiden transgenic 
mice. These mice express the human APOE*3-Leiden gene, resulting in a lipoprotein 
profile reminiscent of that of patients with dysbetalipoproteinemia, marked by elevated 
plasma cholesterol and triglyceride levels that are mainly confined to the VLDL/LDL-sized 
lipoprotein fraction
14
. In contrast to other mice, APOE*3-Leiden transgenics respond to 
various hypolipidemic drugs in a similar way as humans
15
 and are therefore considered a 











Animals and diet. Male APOE*3-Leiden transgenic mice (10-11 weeks old) were housed in 
a temperature and humidity-controlled environment and were fed a high-fat diet (44 
energy% fat derived from bovine fat, Hope Farms, Woerden, The Netherlands) with free 
access to water for 12 weeks to induce insulin resistance
18
. All animal experiments were 
approved by the Animal Ethics Committee from the Leiden University Medical Center, 
Leiden, The Netherlands. 
 
Drugs. GLP-1M was constructed by fusing a GLP-1 peptide analogue to a flexible Gly/Ser 
linker and a fragment of a V region heavy chain (VH) domain linked directly to the CH2 and 
CH3 domains of an Fc as described previously for CNTO736
19
. Ex-4 (molecular weight = 
4186.57 g/mol) was purchased from Sigma (St. Louis, MO).   
 
Treatment. After 8 weeks of high-fat-feeding, mice were divided into 6 groups, matched 
for body weight and fasting plasma triglyceride (TG) concentration. The groups received 
daily subcutaneous (s.c.) doses of GLP-1M (0.3, 0.1, or 0.03 mg/kg, dissolved in PBS), 
CNTO736 (0.3 mg/kg, dissolved in PBS), Ex-4 (7.1 µg/kg, dissolved in PBS), or PBS in a 
volume of 100 µl at 08.00 a.m. during the last 4 weeks on diet. At 08.00 a.m. on the last 
day of the 12 week high-fat diet period, animals were given a last s.c. dose and the 
experiments were initiated 7 hours later. 
 
Plasma lipid and lipoprotein analysis. Blood was collected by tail bleeding into chilled 
paraoxon-coated capillary tubes (Sigma) to prevent ongoing in vitro lipolysis
20
. The tubes 
were placed on ice and centrifuged, and the obtained plasma was snap-frozen in liquid 
nitrogen and stored at -20°C. Plasma was assayed for glucose, FFA, TG, and cholesterol 
using commercially available enzymatic kits (Instruchemie, Delfzijl, The Netherlands), and 
insulin concentrations were measured by ELISA (Mercodia AB, Uppsala, Sweden). Lipid 
distribution over plasma lipoproteins by fast-performance liquid chromatography was 
determined as described before
21
. Fractions of 50 µl were collected and assayed for TG 
and cholesterol as described above. 
Hepatic VLDL particle production. Mice were fasted for 7 hours during the light period 
and anesthetized with an intraperitoneal injection of acepromazine 6.25 mg/kg 
acepromazine (Alfasan, Woerden, The Netherlands), 6.25 mg/kg midazolam (Roche, 
Mijdrecht, The Netherlands), and 0.3125 mg/kg fentanyl (Janssen-Cilag, Tilburg, The 
Netherlands). Mice received an intravenous injection of 100 µl PBS containing 150 µCi 
Tran
35
S label (GE Healthcare, Little Chalfont, U.K.) which binds to newly produced 
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apolipoprotein B (apoB) required for the generation of liver-derived VLDL. After 30 min, 
the animals received a 15% (by volume) intravenous injection of Triton WR-1339 (500 
mg/kg body weight; Tyloxapol, Sigma) to prevent systemic lipolysis of newly secreted 
hepatic VLDL-TG
22
. Blood samples were drawn before (time point 0) and 10, 20, 40, and 60 
min after injection. Plasma was assayed for TG as described above. After the last sampling, 
mice were sacrificed by cervical dislocation and exsanguinated via the retro-orbital plexus 
for isolation of VLDL. Livers were immediately removed from the mice and snap-frozen in 
liquid nitrogen for determination of hepatic lipid content. VLDL was quantitatively isolated 
from plasma after density gradient ultracentrifugation at d<1.006g/ml by aspiration
23
. TG 
and total cholesterol were determined as described above. Phospholipids were 
determined using a standard commercial kit (Spinreact, Sant Esteve de Bas, Spain). VLDL-
apoB was selectively precipitated with 2-propanol
24




Hepatic lipid content. Liver tissue samples were homogenized in PBS (approx. 10% wet 
w/v), and the protein content was measured according to the method of Lowry et al 
25
. 
For analysis of liver lipids, 0.4 ml aliquots of tissue were homogenized with 1.5 ml 
methanol-chloroform (2:1). The homogenate was then centrifuged (2,000 rpm for 5 min) 
and 0.5 ml chloroform and 0.5 ml distilled water were added to the liquid phase, and the 
samples were vortexed. Phase separation was accomplished by centrifugation (2,000 rpm 
for 5 min), where after the bottom phase was removed to a new tube and the samples 
were dried in a nitrogen flow at 50ºC. The pellet was dissolved in 100 µl 2% Triton X-100 in 
chloroform. TG and cholesterol concentrations were determined as described above. 
 
Real-time PCR. Real-time polymerase chain reaction (RT-PCR) was used to measure mRNA 
expression levels of liver genes known to play important roles in TG and cholesterol 
homeostasis (fatty acid synthase (fas), acetyl-Coenzyme A carboxylase alpha (acaca), 
apob, microsomal triglyceride transfer protein (mttp), ATP-binding cassette, sub-family A 
(ABC1), member 1 (abca1), sterol regulatory element binding protein 1 (srebf1), srebf2, 
farnesoid X-activated receptor (fxr), low density lipoprotein receptor (ldlr), diacylglycerol 
O-acyltransferase 1 (dgat1), cytochrome P450, family 7, subfamily a, polypeptide 1 
(cyp7a1), liver X receptor α (lxrα), lxrβ, peroxisome proliferative activated receptor, alpha 
(pparα), pparγ, and acyl-Coenzyme A oxidase (acox1). Therefore, 2 additional groups of 
APOE*3-Leiden mice were used, which were not subjected to Triton injection, to isolate 
livers. These animals were also maintained on a high fat diet for 12 weeks. During the last 
4 weeks on diet, mice received daily s.c. injections of GLP-1M (0.3 mg/kg) or PBS. At the 
end of the treatment period of 4 weeks, mice were fasted for 7 hours during the light 




Total RNA was extracted from liver samples using Trizol. The amount of RNA was 
determined by Nanodrop. The quality was checked by the ratio of absorption at 260 nm 
and absorption at 280 nm. cDNA was synthesized from 2 µg of total RNA using RevertAid™ 
First Strand cDNA synthesis kit (Fermentas, Hanover, MD, U.S.A.). For RT-PCR, primer 
assays were ordered by Qiagen, Venlo, the Netherlands. PCR amplification was performed 
in a total reaction volume of 25 µl. The reaction mixture consisted of QuantiFast SYBR 
Green PCR Master Mix (Qiagen), Primer assay, nuclease free water, and cDNA. An identical 
cycle profile was used for all genes: 95°C for 5 min, followed by 95°C for 10 sec and 60°C 
for 30 sec for 40 cycles. Data were analyzed using a comparative critical threshold (Ct) 
method in which the amount of target normalized to the amount of endogenous control 
(GAPDH/HPRT/Cyclophilin) and relative to the control samples is given by 2
-ΔΔCt
. For each 
gene, all samples were run together in duplex allowing relative comparisons of the 
samples of a given gene. 
 
Statistical analysis. Differences between groups were determined with the Kruskal–Wallis 
non-parametric test for k independent samples. When significant differences were found, 
the Mann–Whitney non-parametric test was used as a follow-up test to determine 
differences between two independent groups. A p-value of less than 0.05 was considered 
statistically significant. Data are presented as mean ± SD. 
 
Results 
Plasma metabolites, body weight, and hepatic content. Body weight, fasting plasma 
glucose, insulin, TG, and cholesterol concentrations are shown in table 1. Chronic 
treatment did not alter body weight in any group. Fasting plasma glucose concentration 
was significantly decreased for all drug-treated groups compared to baseline values after 
chronic administration. Insulin levels increased during the last 4 weeks on diet for the 
control group and GLP-1M (0.03 and 0.1 mg/kg), whereas no difference was found for the 
other groups. TG levels decreased in all treated groups compared to baseline values. 
However, significance was found for the lowest dose of GLP-1M only. The groups did not 
differ with respect to fasting plasma FFA levels. Plasma cholesterol levels significantly 
decreased after 4 weeks of treatment with 0.3 mg/kg GLP-1M and CNTO736 compared to 
baseline values.   
 Lipoprotein fractionation by fast performance liquid chromatography showed no 
differences in distribution for TG concentration (figure 1a). However, cholesterol 
concentration was considerably lower in the VLDL fraction of 0.3 mg/kg GLP-1M and 
CNTO736 treated animals compared to controls. In addition, cholesterol concentration 
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was increased in the HDL fraction for the GLP-1M and CNTO736 treated mice compared to 
controls (Figure 1b).  
 Hepatic TG and total cholesterol content did not differ between groups (table 2). 
 
Table 1. Plasma parameters in APOE*3-Leiden mice at the start and after 2 and 4 weeks of chronic injections with vehicle, GLP-
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Figure 1. Effect of chronic treatment with vehicle, GLP-1M (0.03, 0.1, or 0.3 mg/kg), CNTO736, or exendin-4 on the distribution of 






Table 2. Effect of chronic treatment with vehicle, GLP-1M (0.03, 0.1, or 0.3 mg/kg), CNTO736, or exendin-4 on hepatic lipid 
content.  
Intervention Triglycerides (µg/mg protein) Total cholesterol (µg/mg protein) 
Control 563 ± 129 152 ± 50 
GLP-1M (0.03 mg/kg) 490 ± 91 131 ± 22 
GLP-1M (0.1 mg/kg) 478 ± 166 131 ± 29 
GLP-1M (0.3 mg/kg) 486 ± 178 152 ± 56 
CNTO736 (0.3 mg/kg) 534 ± 104 148 ± 26 
Exendin-4 492 ± 120 155 ± 43 
 
Values represent mean ± SD for at least 8 mice per group. 
 
VLDL production. Chronic treatment with GLP-1M and CNTO736 reduced plasma TG 
concentrations after Triton injection, a measure of VLDL-TG production rate, compared to 
control animals. Ex-4 treatment had no effect whatsoever on VLDL production (figure 2). 
Analysis of the composition of the VLDL particles revealed no differences between groups 
(table 3). The de novo total apoB production rate in newly synthesized VLDL particles was 
significantly lower in mice treated with 0.3 mg/kg GLP-1M and CNTO736 compared to 
controls. No effect on apoB production was found for Ex-4 treated animals compared to 
controls (figure 3). 
 
 
Figure 2. TG concentrations (A) and VLDL-TG production rate (B) in APOE*3-Leiden mice that received chronic injections with 
vehicle, GLP-1M (0.03, 0.1, or 0.3 mg/kg), CNTO736, or exendin-4 after Triton injection. Values represent mean ± SD for at least 8 
mice per group. *P<0.05 vs. control. #P<0.05 vs. exendin-4. 
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Table 3. Lipid composition of nascent VLDL of APOE*3-Leiden mice that received chronic injections with vehicle, GLP-1M (0.03, 
0.1, or 0.3 mg/kg), CNTO736, or exendin-4.  
 
Intervention 
Cholesterol Triglycerides Phospholipids 
                                                     % of total lipid 
Control     20 ± 3      67 ± 4      13 ± 2 
GLP-1M (0.03 mg/kg)     21 ± 4      67 ± 5      12 ± 4 
GLP-1M (0.1 mg/kg)     19 ± 5      68 ± 3      13 ± 2 
GLP-1M (0.3 mg/kg)     17 ± 5      71 ± 7      12 ± 6 
CNTO736 (0.3 mg/kg)     19 ± 5      73 ± 6      10 ± 5 
Exendin-4     19 ± 5      68 ± 7      13 ± 2 
 






S]apoB production in APOE*3-Leiden 
mice that received chronic injections with vehicle, GLP-1M 
(0.03, 0.1, or 0.3 mg/kg), CNTO736, or exendin-4 after 
Triton injection. Values represent mean ± SD for at least 8 
mice per group. *P<0.05 vs. control and exendin-4 
Figure 4. mRNA fold expression levels of different proteins 
in liver of APOE*3-Leiden mice that received chronic 
injections with vehicle or GLP-1M (0.3 mg/kg). Values 




Real-Time PCR. Chronic treatment with GLP-1M (0.3 mg/kg) resulted in a significant 
downregulation of apob and ppary (figure 4). A trend towards downregulation was seen 
for ldlr (p=0.09) and dgat1 (p= 0.09) and a trend towards upregulation for abca1 (p=0.10). 
However, the difference with the control group for these latter genes did not reach 








Here we show that GLP-1M, a GLP-1 receptor agonist, dose-dependently inhibits VLDL-TG 
release in diet-induced insulin resistant APOE*3-Leiden mice. The rate of appearance of 
apoB, an important component of VLDL particles, was diminished as well, indicating that 
the drug curtails the number of particles produced. The reduction of apoB output was 
corroborated by a decline of apob mRNA expression in the liver. The composition of VLDL 
particles was not affected by GLP-1M. Remarkably, Ex-4 did not impact on VLDL-TG 
production, although it did reduce plasma glucose levels to an extent that was similar to 
that brought about by both other drugs. Finally, chronic treatment with GLP-1M (but not 
Ex-4) decreased circulating (fasting) cholesterol levels and shifted the distribution of 
cholesterol among distinct plasma lipoprotein fractions toward HDL.  
 GLP-1M appears to inhibit VLDL-TG production in APOE*3-Leiden mice 
maintained on a high fat diet. Changes in VLDL-TG production are due to alterations in the 
amount of TG per VLDL particle, by the number of particles secreted (as reflected by apoB 
output), or both
26
. The lipid composition of nascent VLDL did not differ between groups. 
However, the VLDL-apoB production rate was significantly decreased by GLP-1M. These 
data suggest that GLP-1M particularly inhibits the production of particles, leaving their 
composition unaffected. Interestingly, overproduction of VLDL particles of normal size and 
composition is the hallmark of diabetic dyslipidemia in humans
11
. 
The effect of GLP-1M on VLDL-TG production may be attributable to a direct 
effect of the drug on apob gene expression. The availability of apoB and substrate play key 
roles in the control of VLDL production
27
 and insulin inhibits VLDL particle assembly at 
multiple levels
28, 29
. GLP-1M did not reduce hepatic triglyceride stores to explain its impact 
on VLDL particle production. Our high-fat-fed mice were insulin resistant, as reflected by 
high plasma glucose and insulin levels in fasting condition, and insulin resistance is 
associated with increased VLDL-apoB production in mice and humans
30, 31
. The 
mechanistic details of insulin action on apoB metabolism are not completely known, but 
may involve the modulation of apoB mRNA translation
32
. Thus, it is conceivable, that GLP-
1M inhibits the production of VLDL particles in high-fat-fed mice by rescuing hepatic 
insulin sensitivity, thereby reducing the efficacy of apoB mRNA translation. However, Ex-4 
did not affect VLDL-TG production, while it reduced circulating glucose concentrations to a 
similar extent as GLP-1M did. Moreover, in a previous study we showed that CNTO736 
inhibits VLDL-TG release whereas Ex-4 (in a dose of 7.1 µg/kg similar to the dose used in 
the present study) does not, even though both drugs have similar effects on insulin 
sensitivity of glucose metabolism
13
. It needs to be emphasized, that our current data 
suggest that the dose of Ex-4 we used may have been too low to fully mimic the impact of 
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the highest dose of GLP-1M on insulin sensitivity, given the (not significantly) lower 
plasma glucose levels during GLP-1M treatment. Nevertheless, we consider it unlikely that 
GLP-1M inhibits VLDL-TG production primarily through its beneficial effect on insulin 
action. GLP-1M clearly diminished apob expression in the liver. We speculate that this 
pharmacological feature of the drug is primarily responsible for its effect on VLDL particle 
production. Indeed, GLP-1 was shown to inhibit lymphatic apoB output, supporting a role 
of this peptide in the control of apoB production
33
. The lack of effect of Ex-4 in this context 
warrants further study. 
 The inhibition of VLDL-TG production by GLP-1M did not result in decreased 
plasma TG levels, which is also true for CNTO736
13
. Thus, other mechanisms that 
determine plasma VLDL-TG levels (e.g. rates of endothelial binding and subsequent 
lipolysis by LPL, and/or the rates of removal of small VLDL from the circulation or its 
conversion to IDL) must have been affected by GLP-1M as well. The drug did not affect the 
distribution of TG among the various lipoprotein subfractions, suggesting that it does not 
impact on VLDL to IDL conversion. Various factors, including the triglyceride and apoE 
content of VLDL particles, modulate epithelial binding and subsequent lipolysis
34
. Although 
the TG content of VLDL particles was not affected by GLP-1M treatment, the drug may 
have modified other features of VLDL particles that determine clearance. Also, uptake of 
small VLDL particles by the liver may have been affected. Obviously, evaluation of these 
hypotheses requires further study. 
 Chronic treatment with 0.3 mg/kg GLP-1M and CNTO736 decreased total 
cholesterol levels in plasma, and Ex-4 (in the current dose) did not appear to exert this 
effect. Cholesterol is removed from the circulation by uptake of lipoproteins in various 
tissues via receptor mediated pathways
35
. Uptake in the liver occurs primarily via the LDL 
receptor. Subsequently, cholesterol enters the entero-hepatic bile acid circulation to be 
partly disposed of via the faeces. Ldlr expression tended to be diminished by GLP-1M, 
suggesting that clearance via this receptor does not explain the drug’s effect on circulating 
cholesterol concentrations. Alternatively, excess cholesterol was directed towards the 
liver via HDL lipoproteins to be disposed of via bile. Hepatic cholesterol content was not 
affected by GLP-1M, suggesting that increased supply of (HDL) cholesterol was offset by 
enhanced removal via the bile
36
. Preliminary studies indicate that both sterol and bile acid 
secretion were increased indeed by chronic treatment with GLP-1M (Parlevliet et al., data 
not shown). 
GLP-1M (and CNTO736) shifted the distribution of cholesterol among distinct 
lipoprotein fractions toward HDL, suggesting that the drug somehow promotes efficient 
clearance of cholesterol from chylomicrons, VLDL, and IDL by extrahepatic tissues to form 




export of hepatic cholesterol towards nascent HDL by ABCA1 is rate-limiting in the process 
of HDL formation
37
. Abca1 expression in the liver was increased in GLP-1M treated animals 
as compared with placebo treated controls, but the difference did not reach statistical 
significance. HDL metabolism is also controlled by the concerted impact of a number of 
plasma proteins such as phospholipid transfer protein, lecithin-cholesterol acyltransferase, 
endothelial-bound enzymes LPL and hepatic lipase, and GLP-1M may modulate the 




 Our data suggest that GLP-1M may have powerful anti-atherogenic properties in 
insulin resistant subjects. Atherosclerosis is driven by increased (VLDL) cholesterol and 
triglyceride levels, often accompanied by low circulating HDL concentrations
41
. HDL 
particles are anti-atherogenic, partly because of their role in reverse cholesterol transport, 
but also because of their anti-oxidative, anti-inflammatory, anti-thrombotic, and anti-
apoptotic properties
42-44
. Therefore, the reduction of plasma cholesterol concentration by 
GLP-1M as well as its capacity to increase HDL cholesterol levels holds promise as 
pharmacological features preventing atherosclerosis in high risk metabolic conditions.  
 The current study suggests that GLP-1M has properties not reported for a GLP-1 
analogue thus far. Chronic administration of the drug in high-fat-fed APOE*3-Leiden mice 
clearly inhibited VLDL-TG production. Moreover, chronic GLP-1M administration 
decreased total cholesterol levels and increased HDL in the same experimental context. 
Chronic administration with Ex-4 did not impact on VLDL or cholesterol metabolism, 
suggesting that the GLP-1M effects on lipid metabolism are not mediated via its impact on 
insulin sensitivity.  
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Glucagon-like peptide-1 (GLP-1) improves insulin sensitivity in humans and rodents. It is 
currently unknown to what extent the (metabolic) effects of GLP-1 treatment are 
mediated by central GLP-1 receptors. We studied the impact of central GLP-1 receptor 
(GLP-1R) antagonism on the metabolic effects of peripheral GLP-1 administration in mice. 
High-fat-fed insulin resistant C57Bl/6 mice were treated with continuous subcutaneous 
infusion of GLP-1 or saline (PBS) for 2 weeks, while the GLP-1R antagonist exendin-9 (EX-9) 
or cerebral spine fluid (CSF) were simultaneously infused in the left lateral cerebral 
ventricle (icv). Glucose and glycerol turnover were determined during a hyperinsulinemic 
euglycemic clamp. VLDL-triglyceride (VLDL-TG) production was determined in 
hyperinsulinemic conditions. Our data show that the rate of glucose infusion necessary to 
maintain euglycemia was significantly increased by GLP-1. Simultaneous icv infusion of EX-
9 diminished this effect by 62%. The capacities of insulin to stimulate glucose disposal and 
inhibit glucose production were reinforced by GLP-1. Simultaneous icv infusion of EX-9 
significantly diminished the latter effect. Central GLP-1R antagonism alone did not affect 
glucose metabolism. Also, GLP-1 treatment reinforced the inhibitory action of insulin on 
VLDL-TG production. In conclusion, peripheral administration of GLP-1 reinforces the 
ability of insulin to suppress endogenous glucose- and VLDL-TG production (but not 
lipolysis), and boosts its capacity to stimulate glucose disposal in high-fat-fed C57Bl/6 
mice. Activation of central GLP-1 receptors contributes substantially to the inhibition of 
endogenous glucose production by GLP-1 treatment in this animal model. 




Glucagon-like peptide-1 (GLP-1) is produced by entero-endocrine L-cells in response to 
food intake
1, 2
. Circulating GLP-1 plays a major role in the control of postprandial 
metabolism, as it augments nutrient induced insulin release
1, 3
, inhibits glucagon 
secretion
4
, and reduces endogenous glucose production (EGP) through (peripheral?) 
mechanistic routes that appear to be independent of islet hormones
5
. Circulating GLP-1 
also inhibits food intake, probably via vagal afferents activating neurons in the nucleus of 
the solitary tract that subsequently project to hypothalamic neurons to blunt appetite
6, 7
. 
Thus, circulating GLP-1 has multiple effects on postprandial behaviour and metabolism to 
coordinate the systemic response to food intake. 
GLP-1 is also produced in a discrete population of neurons in the hind brain
8, 9
, and GLP-1 
fibers terminate in the arcuate and paraventricular nucleus of the hypothalamus
9
, brain 
areas that play key roles in the control of metabolism
10
. GLP-1 receptors are abundantly 
expressed in these nuclei
11, 12
, and recent evidence indicates that activation of arcuate 
GLP-1 receptors sensitizes the liver to insulin, at least as far as its impact on glucose 
production is concerned
13
. Despite compelling evidence that GLP-1 can cross the blood 
brain barrier
14
, peripheral and central GLP-1 signaling systems are generally considered as 
separate regulatory circuits. To date, GLP-1 effects on insulin action have only been 
reported as a result of central GLP-1 receptor activation
13, 15
. We have recently shown that 
peripheral administration of a novel GLP-1 agonist ameliorates insulin resistance of 
glucose and VLDL-triglyceride (VLDL-TG) metabolism in high-fat-fed C57Bl/6J mice
16
. It is 
currently unknown to what extent the (metabolic) effects of GLP-1 treatment are 
mediated by central GLP-1 receptors. Here, we aimed to evaluate the impact of blocking 
central GLP-1 receptors on the metabolic effects of peripherally administered GLP-1. Our 
data show beneficial effects of GLP-1 treatment on glucose and lipid metabolism in insulin 
resistant high-fat-fed mice. GLP-1 enhanced insulin’s action to inhibit glucose production 
via activation of central GLP-1 receptors. 
 
Material and Methods 
Animals and diet. Male C57Bl/6J mice (12 weeks old) (Charles River, Maastricht, the 
Netherlands) were housed in a temperature and humidity-controlled environment on a 
12-h light-dark cycle (lights on from 7:00 – 19:00) and were fed a high-fat diet (44 energy% 
fat derived from bovine fat, Hope Farms, Woerden, The Netherlands) with free access to 
water for 16 weeks to induce insulin resistance
17, 18
. All animal experiments were 
approved by the Animal Ethics Committee from the Leiden University Medical Center, 





Drugs. GLP-1 (7-36) (human, bovine, guinea pig, mouse, rat; molecular weight: 3297.68 
g/mol) and EX-9 (molecular weight: 3369.80 g/mol) were purchased from Bachem (Weil 
am Rhein, Germany). 
 
Surgical procedures. For intracerebroventricular (icv) cannula implantation, mice were 
anaesthetized with 0.5 mg/kg medetomidine (Orion Corp. Espoo, Finland), 5.0 mg/kg 
midazolam (Roche, Mijdrecht, The Netherlands), and 0.05 mg/kg fentanyl (Bipharma, 
Weesp, The Netherlands). A 30-gauge guide cannula (Brain infusion kit 3, Alzet, DURECT 
Corp., Cupertino, CA) was stereotactically implanted in the left lateral ventricle using the 
following coordinates from Bregma: 0.46 mm posterior, 1.0 mm lateral, and 2.2 mm 
ventral. The guide cannula was connected to an osmotic minipump (model 1004, Alzet) via 
a catheter. This catheter was filled with artificial cerebral spine fluid (CSF, Harvard 
Apparatus, Natick, MA, US) to delay the start of delivery of the drug by 5 days. A small air 
bubble was introduced to separate the drug from the CSF. The minipump was placed sc in 
the right back region, for the continuous delivery of 0.5 pmol/kg/min EX-9 (dissolved in 
CSF) or CSF at a rate of 0.11 µl/h as a control. This dose of EX-9 is known to specifically 
block the central (but not peripheral) GLP-1 receptors
15
. The anaesthesia was antagonized 
using 2.5 mg/kg antipamezol (Pfizer, Capelle a/d IJssel, The Netherlands), 0.5 mg/kg 
flumazenil (Roche), and 1.2 mg/kg naloxon (Orpha, Purkersdorf, Austria). Post-operative 
analgesia was provided by sc administration of 0.05 mg/kg buprenorphine (Temgesic®, 
Schering-Plough, Amstelveen, The Netherlands). In addition, antibiotic (cefazoline, 50 
mg/kg) was sc injected. After 5 days of recovery (on the day the icv EX-9/CSF treatment 
started), mice were matched for body weight and non-fasting glucose levels and a second 
minipump (model 1002, Alzet) was implanted subcutaneously in the left back region under 
light isoflurane anaesthesia for the continuous sc delivery of 3 pmol/kg/min GLP-1 
(dissolved in PBS) to increase plasma GLP-1 levels
19
 or PBS as a control. We chose a two 
times higher dose of GLP-1 than referred to, since that dose did not result in a significant 
decrease in non-fasting glucose levels throughout the treatment. After the surgical 
procedures, we ended up with four groups, from now on referred to by the routes of 
administration (icv/sc) and names of the compounds: CSF/PBS, CSF/GLP-1, EX-9/PBS, and 
EX-9/GLP-1. After 2 weeks of intervention experiments were performed as described 
below. At the end of the experiment, dye (0.5% Evans Blue) was injected through the 
cannula to confirm its position in the ventricle. Only mice with correct placement of 
cannulas were included in the final analysis. 
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Hyperinsulinemic euglycemic clamp. Mice were fasted prior to the clamp for 16 hours 
overnight with food withdrawn at 1700 h the day before the study. Hyperinsulinemic 
euglycemic clamp experiment was performed as described before
20, 21
. During the 
experiment, mice were sedated with 6.25 mg/kg acepromazine (Alfasan, Woerden, The 
Netherlands), 6.25 mg/kg midazolam (Roche, Mijdrecht, The Netherlands), and 0.3125 
mg/kg fentanyl (Janssen-Cilag, Tilburg, The Netherlands). First, basal rates of glucose and 
glycerol turnover were determined by isotope dilution methodology using a primed (p) 
continuous (c) iv infusion of [1-14C]Glucose (p: 0.2 µCi; c: 0.3 µCi/h, GE Healthcare, Little 
Chalfont, U.K.) and [1-(3)-3H]Glycerol (p: 0.6 µCi; c: 0.9 µCi/h, GE Healthcare) for 60 
minutes. The choice of these tracers may not be that common. However, in the past we 
did not found any important differences with other papers and theoretically do not expect 
any problems by using these tracers. We are aware that the disadvantage of most 14C-
glucose tracers is that they are reversible isotopes, i.e. a fraction of the labelled 
breakdown products is reincorporated in the mother compound, resulting in an 
underestimation of the rate of appearance. However, it is important to also recognize that 
other tracers have their own problems. With 3H-glucose for example, recycling occurs 
with unlabeled glucose via glucose cycling from fructose-6-phosphate etc. Also, part of the 
glucose is lost in the hexose monophosphate pathway
22
. After the basal period, insulin 
(Actrapid, Novo Nordisk, Denmark) was administered in a primed (4.5 mU) continuous (6.8 
mU/h) iv infusion for 90 minutes to attain steady state circulating insulin levels of ~5 
ng/ml. A variable iv infusion of a 12.5% D-glucose solution was used to maintain 
euglycemia as determined at 10 min intervals via tail bleeding (< 3 µl) (Accu-chek, Sensor 
Comfort, Roche Diagnostics GmbH, Mannheim, Germany). Blood samples (60 µl) were 
taken via tail bleeding during the basal period (after 50 and 60 min) and during the clamp 
period (after 70, 80, and 90 min) to determine plasma concentrations of glucose, non-
esterified fatty acids (NEFA), insulin, glycerol, and plasma [1-14C]Glucose and [1-(3)-
3H]Glycerol specific activities. At the end of the clamp, VLDL-production was quantified. 
 
VLDL-TG production. VLDL-TG production was determined during continuous insulin 
infusion (6.8 mU/h) directly after the clamp experiment. At t=0 min blood was taken via 
tail bleeding and mice were iv injected with 500 mg of tyloxapol (Triton WR-1339, Sigma-
Aldrich) per kg body weight as a 10% (w/w) solution in sterile saline in a total volume of 
150 µl. This completely blocked VLDL clearance from serum
23
. Additional blood samples 
(20 µl) were taken at t=10, 20, 40, and 60 min after tyloxapol injection and used for 
determination of plasma TG concentration. After the last sampling, mice were sacrificed 





Analytical procedures. Commercially available kits were used to determine plasma levels 
of glucose, NEFA, TG (Instruchemie, Delfzijl, The Netherlands), and free glycerol (Sigma, 
MO, US). Plasma insulin concentration was measured by ELISA (Crystal Chem. Inc., 
Downers Grove, IL, USA). Total plasma [1-14C]Glucose and [1-(3)-3H]Glycerol were 
determined in 8 µl plasma and in supernatants after trichloroacetic acid (20%) 
precipitation and water evaporation to eliminate tritiated water. 
 
Calculations. The turnover rates of glucose and glycerol (µmol/min/kg) were calculated 
during the basal period and under steady-state clamp conditions as the rate of tracer 
infusion (dpm/min) divided by the plasma-specific activity of [1-14C]Glucose or [1-(3)-
3H]Glycerol (dpm/µmol). The ratio was corrected for body weight. EGP was calculated as 
the difference between the tracer-derived rate of glucose appearance and the glucose 
infusion rate (GIR). Hepatic VLDL-TG production rates (µmol/h/kg) were calculated from 
the linear increase in plasma TG concentrations in time. All metabolic parameters were 
expressed per kg of body weight. 
 
Statistical analysis. Statistical analysis was performed using SPSS. Differences between 
groups were determined with the Kruskal–Wallis non-parametric test for k independent 
samples. When significant differences were found, the Mann–Whitney non-parametric 
test was used as a follow-up test to determine differences between two independent 
groups. Effects on the suppression of glycerol turnover between groups were assessed by 
repeated measure ANOVA. A P-value of less than 0.05 was considered statistically 
significant. Data are presented as mean ± SD. 
 
Results 
Body weight and plasma parameters. Fasting body weights, plasma glucose, insulin, 
glycerol, and NEFA concentrations in basal and hyperinsulinemic conditions are shown in 
Table 1. Body weight did not differ and plasma glucose and insulin levels were similar in all 
groups, both in basal and hyperinsulinemic conditions. Insulin infusion reduced plasma 
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Table 1. Body weight and plasma parameters in basal and hyperinsulinemic conditions in mice that received chronic 
intracerebroventricular/subcutaneous infusion of CSF/PBS, CSF/GLP-1, EX-9/PBS, or EX-9/GLP-1. Values represent mean ± SD for 
at least 9 mice per group. 
  CSF/PBS CSF/GLP-1 EX-9/PBS EX-9/GLP-1 
Body weight (g)  33.2 ± 2.7 32.2 ± 2.3 33.0 ± 4.0 33.3 ± 2.6 
Glucose (mM) Basal 5.11 ± 0.71 4.39 ± 0.81 5.16 ± 0.88 5.20 ± 0.83 
 Hyperinsulinemic 5.04 ± 0.89 4.31 ± 0.65 5.37 ± 1.10 5.16 ± 0.90 
Insulin (ng/ml) Basal 0.87 ± 0.44 0.73 ± 0.24 0.98 ± 0.76 0.85 ± 0.57 
 Hyperinsulinemic 4.84 ± 0.92 5.33 ± 1.32 4.88 ± 1.02 5.22 ± 1.61 
Glycerol (mM) Basal 0.12 ± 0.03 0.14 ± 0.04 0.13  ± 0.04 0.14 ± 0.05 
 Hyperinsulinemic 0.09 ± 0.03 0.09 ± 0.02 0.10  ± 0.03 0.10 ± 0.03 
FFA (mM) Basal 0.67 ± 0.13 0.68 ± 0.18 0.68 ± 0.14 0.68 ± 0.12 
 Hyperinsulinemic 0.39 ± 0.10 0.36 ± 0.07 0.41 ± 0.08 0.39 ± 0.10 
 
Glucose turnover. In basal conditions, glucose turnover was not different between groups 
(CSF/PBS: 36 ± 8; CSF/GLP-1: 34 ± 6; EX-9/PBS: 35 ± 7; EX-9/GLP-1: 36 ± 6 µmol/min/kg). 
During hyperinsulinemia, plasma glucose levels were successfully clamped at ~5 mM 
(figure 1A). The GIR required to maintain euglycemia was more than twice as high in GLP-1 
treated animals compared to controls (CSF/PBS: 17 ± 10; CSF/GLP-1: 43 ± 9 µmol/min/kg, 
P<0.01), indicating that GLP-1 reinforces whole body insulin action in this experimental 
context (figure 1B). Blocking the central GLP-1 receptors by icv infusion of EX-9 clearly 
blunted the effect of GLP-1 on GIR by 62% (EX-9/GLP-1: 27 ± 11 µmol/min/kg, P<0.01 vs. 
CSF/GLP-1). Central GLP-1 receptor antagonism by itself did not affect GIR (EX-9/PBS: 20 ± 
13 µmol/min/kg). 
Hyperinsulinemia increased glucose disposal in all groups (figure 2A). However, the 
disposal rate was significantly higher in GLP-1 treated animals compared to controls 
(CSF/PBS: 46 ± 7; CSF/GLP-1: 53 ± 6 µmol/min/kg, P<0.05). Simultaneous icv infusion of 
EX-9 had no effect (EX-9/GLP-1: 53 ± 10 µmol/min/kg). Also, icv infusion of EX-9 alone did 
not affect insulin mediated glucose disposal (EX-9/PBS: 43 ± 7 µmol/min/kg).  
EGP during insulin infusion is shown in figure 2B. GLP-1 treatment enhanced insulin’s 
capacity to inhibit EGP (CSF/PBS: 28 ± 12; CSF/GLP-1: 13 ± 9 µmol/min/kg, P<0.01) and 
simultaneous icv infusion of EX-9 significantly blunted this effect by 61% (EX-9/GLP-1: 22 ± 
9 µmol/min/kg vs. CSF/GLP-1, P<0.05). Icv infusion of EX-9 alone did not affect EGP (EX-





Glycerol turnover.  Lipolysis, as reflected by basal rates of glycerol turnover, was not 
different between groups in basal condition (CSF/PBS: 3.0 ± 0.7; CSF/GLP-1: 3.5 ± 0.9; EX-
9/PBS: 3.1 ± 0.8; EX-9/GLP-1: 3.4 ± 1.3 µmol/min/kg). Glycerol turnover was significantly 
reduced during hyperinsulinemia only in GLP-1 treated animals (CSF/PBS: 2.9 ± 1.1; 
CSF/GLP-1: 2.7 ± 0.7; EX-9/PBS: 2.8 ± 1.1; EX-9/GLP-1: 2.9 ± 0.9 µmol/min/kg; figure 3). 
However, the effect expressed as percentage reduction of baseline values was not 
significantly different between interventions (CSF/PBS: 18 ± 15; CSF/GLP-1: 20 ± 17; EX-
9/PBS: 19 ± 21; EX-9/GLP-1: 19 ± 20 % reduction from baseline)  
 
Figure 1. Plasma glucose (A) and glucose infusion rate (B) 
during a hyperinsulinemic euglycemic clamp in mice that 
received chronic intracerebroventricular/ subcutaneous 
infusion of CSF/PBS, CSF/GLP-1, EX-9/PBS, or EX-9/GLP-1. 
Values represent mean ± SD for at least 9 mice per group. 
*p <0.05 vs. control. **p <0.01 vs. control. 
Figure 2. Glucose uptake (A) and glucose production (B) 
during a hyperinsulinemic euglycemic clamp in mice that 
received chronic intracerebroventricular/ subcutaneous 
infusion of CSF/PBS, CSF/GLP-1, EX-9/PBS, or EX-9/GLP-1. 
Values represent mean ± SD for at least 9 mice per group. 
*p <0.05 vs. control. **p <0.01 vs. control. 
 
VLDL-TG production. Plasma TG levels (figure 4) and hence, VLDL-TG production rate in 
hyperinsulinemic condition were significantly reduced by GLP-1 treatment (CSF/PBS: 252 ± 
47; CSF/GLP-1: 205 ± 31 µmol/h/kg, P<0.05). Simultaneous icv infusion of EX-9 did not 
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significantly impact on this effect (EX-9/GLP-1: 216 ± 39 µmol/h/kg) and icv infusion of EX-
9 alone did not affect VLDL-TG production (EX-9/PBS: 249 ± 40 µmol/h/kg). 
 
 
Figure 3. Glycerol turnover before (basal) and after 
(hyperinsulinemic) the initiation of a hyperinsulinemic 
euglycemic clamp in mice that received chronic 
intracerebroventricular/subcutaneous infusion of 
CSF/PBS, CSF/GLP-1, EX-9/PBS, or EX-9/GLP-1. Values 
represent mean ± SD for at least 9 mice per group. *p 
<0.05 vs. control. 
Figure 4. Triglyceride (TG) concentrations during 
hyperinsulinemia after tyloxapol infusion in mice that 
received chronic intracerebroventricular/  subcutaneous 
infusion of CSF/PBS, CSF/GLP-1, EX-9/PBS, or EX-9/GLP-1. 
Values represent mean ± SD for at least 9 mice per group. 
*p <0.05 vs. control. 
 
Discussion 
This study shows that chronic subcutaneous administration of GLP-1 enhances whole body 
insulin sensitivity of glucose metabolism in high-fat-fed insulin resistant C57Bl/6J mice. 
This is brought about by the composite stimulatory effects of GLP-1 on the capacity of 
insulin to suppress EGP and stimulate glucose disposal. Moreover, GLP-1 enhanced 
insulin’s ability to inhibit VLDL-TG production in this experimental context. Simultaneous 
icv infusion of EX-9, blocking central GLP-1 receptors, abolished the inhibition of EGP, 
whereas it did not affect VLDL-TG production. Icv infusion of EX-9 alone did not affect 
insulin action in any way. These data show that GLP-1 treatment ameliorates insuline 
resistance in high-fat-fed mice and strongly suggest that it reinforces insulin action to 
suppress endogenous glucose production via central GLP-1 receptors. 
 To the best of our knowledge, this is the first study to focus on the role of central 
GLP-1 receptors in the metabolic effects of (pharmacologic levels of) circulating GLP-1. All 
other studies evaluating the behavioural and metabolic effects of central GLP-1 receptor 




GLP-1 receptor antagonists (e.g. refs
13, 15, 24
). Our data suggest that peripheral GLP-1 
treatment modulate insulin action via central receptors, as far as insulin’s ability to inhibit 
glucose production is concerned. This inference is consistent with data indicating that 
circulating GLP-1 has access to the brain
11, 14, 25
. The fact that icv administration of EX-9 
alone did not impact on glucose or lipid metabolism in this experimental context suggest 
that central GLP-1 receptors do not play a major role in the control of (postprandial) fuel 
flux by endogenous GLP-1 (and thereby suggest that a supraphysiological plasma 
concentration of GLP-1 is required to activate central receptors. Although we did not 
measure plasma GLP-1 levels, which is a limitation of this study, we assume GLP-1 levels to 
be considerably increased as observed in a previous experiment of similar design
19
). Gut-
derived circulating GLP-1 is rapidly degraded and blood levels rise only for a limited period 
of time in response to a meal
26
. The kinetics of postprandial GLP-1 production may not 
allow for substantial activation of central receptors in high-fat-fed insulin resistant mice, 
whereas continuous GLP-1 infusion might. This issue clearly requires further study. Our 
data do suggest that GLP-1 analogues, with extended plasma half-lives for therapeutic use, 
act to improve metabolism in part via the brain. 
The beneficial effects of GLP-1 on glucose metabolism corroborate the results of a 
previous study investigating the therapeutic potential of a novel GLP-1 analogue in insulin 
resistant mice
16
. They are also in keeping with earlier reports indicating that GLP-1 and its 
analogues ameliorate whole-body insulin resistance in obese animal models
27, 28
 and in 
T2DM patients
29
. They further extend our knowledge of the precise actions of GLP-1 on 
distinct components of glucose flux in insulin-resistant animals, inasmuch as they show 
that it enhances insulin action on both glucose disposal and production in the long term. 
In apparent contrast, however, a recent paper indicates that central administration of 
GLP-1 hampers insulin mediated glucose disposal in male Long Evans rats, albeit not to a 
major extent
13
. Moreover, another paper consistently reported that icv exendin-4 (a GLP-1 
receptor agonist) acutely impairs insulin’s action on glucose uptake in normal C57Bl/6J 
mice (but only in hyperglycemic conditions)
15
. The same investigators also reported that 
chronic (4 wk) infusion of EX-9 (in a dose that was equal to ours) into the lateral ventricle 
of high-fat-fed male C57Bl/6J mice rescues insulin sensitivity and prevents the onset of 
glucose intolerance in these animals, again suggesting that central GLP-1 receptor 
activation impairs insulin action
30
. Our data unequivocally indicate that peripheral 
administration of GLP-1 enhances insulin sensitivity in the same insulin resistant animal 
model. In particular, they indicate that activation of central GLP-1 receptors contributes 
substantially to the effect of GLP-1 treatment on glucose production. This inference agrees 
with at least one aforementioned study, showing that activation of central GLP-1 
receptors reinforces insulin’s capacity to suppress EGP
13
. It is difficult to reconcile the 
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conflicting results of these studies. One major difference between the design of all other 
experiments and ours is the fact that we studied the effects of peripherally injected GLP-1, 
whereas others evaluated the impact of centrally administered compounds (where 
circulating GLP-1 levels were presumably low). It is conceivable that centrally injected GLP-
1 activates neuronal circuits that are distinct from those activated by circulating GLP-1, 
and therefore exerts differential metabolic effects. However, it remains difficult to 
understand that icv EX-9 alone appears to have no effect on insulin sensitivity in our 
studies, whereas it reinforced insulin action in virtually the same experiment reported by 
Knauf et al
30
. Our study design differed from Knauf’s in that EX-9 was given icv for 4 weeks 
in their experiment, 2 weeks longer than in ours. Thus, the effects observed by Knauf et al 
may have been (indirect) effects of longer term EX-9 treatment. Also, the timing and 
composition of the dietary intervention was somewhat different in the studies by Knauf. 
Experiments were done after 4 weeks of a virtually carbohydrate free diet, while we 
studied animals after 16 weeks on a diet containing approximately 20% of carbohydrate. 
The longer period of high fat feeding may have reduced basal GLP-1 levels and diminished 
the GLP-1 response to food intake
31
. Obviously, a reduction of circulating GLP-1 will blunt 
its impact on insulin action and therefore the effect of (central) GLP-1 receptor 
antagonism on insulin sensitivity. The data clearly warrant further exploration of this 
issue. Finally, the period of fasting prior to the hyperinsulinemic euglycemic clamp was 
different; a 6h fasting period by Knauf vs. a 16h fast in our study, which might have 
contributed to a different peripheral phenotype
32
. 
GLP-1 reinforced the capacity of insulin to inhibit VLDL-TG production. This finding adds to 
our knowledge of the effects of GLP-1 on lipid metabolism. Our observations are fully 
consistent with those reported in one of our previous papers, delineating the metabolic 
effects of a novel GLP-1 analogue in the same animal model
16
. Also, native GLP-1 reduces 
postprandial plasma TG levels in healthy, normal-weight humans and T2DM patients
33, 34
. 
The assembly of VLDL particles in the endoplasmic reticulum of hepatocytes is dependent 
on the intracellular presence of TG, other lipids, and apolipoprotein B (apoB) as its major 
components. Therefore, the availability of apoB and substrates play key roles in the 
control of VLDL production
35
. Insulin inhibits VLDL assembly in multiple ways. It limits the 
flow of fatty acid substrates to the liver by inhibiting (adipocyte) lipolysis and probably 
also modulates apoB mRNA translation
36
. However, GLP-1 did not affect lipolysis or 
insulin’s capacity to suppress this process and, accordingly, it did not change plasma NEFA 
concentrations. Therefore, inhibition of lipolysis is not the route through which GLP-1 
modifies VLDL-TG secretion in high-fat-fed insulin resistant mice. Thus, GLP-1 may 
strengthen the ability of insulin to restrain VLDL-TG production directly by diminishing the 






icv administration of EX-9 did not significantly affect the ability of insulin to suppress VLDL-
TG production. This observation suggests that GLP-1 treatment reinforces the impact of 
insulin on VLDL-TG secretion via peripheral receptors in our experimental set-up. In this 
respect, it is interesting to note the direct role of GLP-1 on human hepatocytes to reduce 
steatosis
38
. However, it is doubtful whether rodent hepatocytes express GLP-1 receptors
39, 
40
. Further investigation of the mechanisms driving GLP-1’s effect on lipid metabolism is 
warranted. 
Despite its unequivocal effects on glucose and VLDL-TG metabolism, GLP-1 did not 
significantly impact on the ability of insulin to inhibit lipolysis. This is consistent with the 
results of a previous study, showing that CNTO736, a novel GLP-1 analogue, ameliorates 
insulin resistance of glucose and VLDL-TG metabolism, but not lipolysis in high-fat-fed 
C57Bl6/J mice
16
. In concert, these studies strongly suggest that GLP-1 exerts tissue specific 
effects on insulin action in high-fat-fed C57Bl/6 mice.  
The neuronal circuits that are activated by circulating GLP-1 and mediate its metabolic 
effects remain to be identified. Larger, blood-born molecules can access the arcuate 
nucleus through local, functional gaps in the blood-brain-barrier
41
. Arcuate neuropeptide Y 
(NPY) and pro-opiomelanocortin neurons are intimately involved in the control of fuel flux. 
Indeed, icv injection of NPY impairs insulin’s ability to suppress glucose production
21
. 
Animal models of obesity and type 2 diabetes (including diet-induced obesity) are marked 
by elevated NPY expression in hypothalamic nuclei
42, 43
(although this has been debated
44, 
45
), and these exceedingly active NPY neurons may drive overproduction of glucose in 
these models. GLP-1 has been reported to prevent the orexigenic effects of NPY possibly 
by reducing hypothalamic NPY mRNA expression
7, 46, 47
). In analogy, peripheral 
administered GLP-1 may have inhibited arcuate NPY neurons to explain the findings on 
glucose turnover presented here. 
 In conclusion, we here show that GLP-1 treatment ameliorates insulin resistance 
of glucose and VLDL-TG metabolism in high-fat-fed mice. In particular, peripheral 
administration of GLP-1 reinforces the capacity of insulin to stimulate glucose disposal and 
inhibit glucose and VLDL-TG production in this model, where central GLP-1 receptors are 
required for the effect on glucose production. 
 
This study was supported by an Amylin Paul Langerhans grant from the European Foundation for the 
Study of Diabetes (EFSD), 2008 (to E.T.P). 
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Obinepitide, a dual-analogue of peptide YY3-36 and pancreatic polypeptide (PP), and 
TM30339, a PP analogue, were developed as anti-obesity drugs. Pre-clinical studies have 
shown long-term effects on decreased body weight in human and animals. Here, we 
further evaluate the potential of these drugs in terms of insulin sensitivity of glucose and 
lipid metabolism. Diet-induced insulin resistant C57Bl/6J mice were daily subcutaneously 
injected with Obinepitide (0.3 and 3.0 mg/kg), TM30339 (0.3 and 3.0 mg/kg), or vehicle for 
4 weeks. Glucose and glycerol turnover were determined during a hyperinsulinemic 
euglycemic clamp. Very low density lipoprotein-triglyceride (VLDL-TG) production was 
determined in basal and hyperinsulinemic conditions after intravenous injection of 
tyloxapol. 3.0 mg/kg Obinepitide and both doses of TM30339 significantly enhanced 
insulin mediated glucose disposal (Obinepitide: 100 ± 26, p<0.01; 0.3 mg/kg TM30339: 90 
± 25, p<0.05; 3.0 mg/kg TM30339: 116 ± 19, p<0.01; control: 62 ± 25 % stimulation). In 
addition, both drugs affected insulin’s capacity to inhibit endogenous glucose production 
(Obinepitide: 51 ± 24, p<0.05; 0.3 mg/kg TM30339: 60 ± 23, p<0.01; 3.0 mg/kg TM30339: 
68 ± 24, P<0.01; control: 30 ± 26 % inhibition). Insulin’s capacity to inhibit glycerol 
turnover was not affected by any of the treatments. In basal conditions, none of the drugs 
affected VLDL-TG production. However, during insulin infusion VLDL-TG production was 
decreased in 3.0 mg/kg treated mice only (3.0 mg/kg TM30339: 134 ± 17; control: 167 ± 
29 µmol/h/kg; p<0.01). The data suggest that Obinepitide and TM30339 appear to be 
useful tools to improve glucose metabolism in diet-induced insulin resistant C57Bl/6J 
mice. 




Peptide YY (PYY) and pancreatic polypeptide (PP) are closely related 36-amino acid 
peptides. PYY is synthesized in the intestinal L-cells, which are predominantly located in 
the distal part of the gastrointestinal tract. PP is synthesized in the so-called F-cells, 
located in the pancreatic islet of Langerhans. Both PYY and PP are released into the 
circulation in response to nutrient intake in proportion to caloric intake
1, 2
. PYY circulates 
primarily as the N-terminally truncated form of the full length peptide, PYY3-36
3
. After 
being released PYY3-36 and PP bind and activate a class of G-protein coupled receptors 
belonging to the neuropeptide Y receptor family. To date 5 subtypes have been identified: 
Y1R, Y2R, Y4R, Y5R, and Y6R
4
. PYY3-36 is known to exert its effects predominantly via the 
Y2R, which are highly expressed in the arcuate nucleus
5
, whereas PP effects are thought to 
be mediated via the Y4R subtype, expressed at many sides in the brain
6
.  
 The central Y receptors are involved in the control of a diverse set of regulatory 
processes, including appetite and body weight. Food intake is significantly reduced after 
peripheral administration of PYY3-36 and PP in both rodents and humans (7-10). Chronic 
PYY3-36 administration reduces body weight
11, 12
. Moreover, PYY overexpression protects 
against diet-induced obesity in mice, whereas ablation of PYY leads to the development of 
obesity
13, 14
. In addition to their roles in feeding and body weight regulation, PYY3-36 and PP 
affect insulin sensitivity in animal models of obesity and type 2 diabetes
12, 15-17
. Specifically, 
for PYY3-36 this is the result of an enhanced insulin mediated glucose disposal 
16, 17
. 
 The aforementioned studies suggest that the Y receptors are interesting targets 
for the treatment of obesity and type 2 diabetes mellitus (T2DM). Selective Y2/Y4 agonists 
may have metabolic effects similar to those of PYY3-36 and PP. In this respect, Obinepitide 
(dual Y2/Y4 receptor agonist) and TM30339 (Y4 receptor agonist), were developed by 7TM 
Pharma (Copenhagen, Denmark) as anti-obesity drugs
18, 19
. Pre-clinical studies have shown 
that Obinepitide reduces the body weight of DIO mice more than native PYY3-36. 
Furthermore, daily sc injections of Obinepitide in obese humans inhibited food intake at a 
statistically significant level up to 9 h after dosing
20
. TM30339 also reduces the body 
weight of DIO mice
21
.  
 Here, we further explore the pharmacological characteristics of Obinepitide and 
TM30339 in terms of their metabolic effects. In particular, we evaluate the chronic impact 
of these compounds on insulin sensitivity of glucose and very low density lipoprotein-
triglyceride (VLDL-TG) metabolism in diet-induced insulin resistant C57Bl/6 mice. 
Overproduction of VLDL-TG, which is a prominent feature of diabetic dyslipidemia (as the 
proximate cause of hypertriglyceridemia), contributes significantly to cardiovascular risk in 
T2DM patients
22
. Neuropeptide Y (NPY), also acting via the Y receptors, has been shown to 
stimulate VLDL production
23, 24






 (and possibly PYY exerts the same effects on NPY via the Y4R), we therefore 
hypothesized that Obinepitide and TM30339 would inhibit VLDL-TG production. 
 
Methods 
Animals. 12 week old male C57BL/6J mice (Charles River, Maastricht, The Netherlands) 
were housed in a temperature-controlled room on a 12-hour light-dark cycle (lights on 
from 7:00 – 19:00) and fed a high fat diet (44 energy% fat derived from bovine fat, Hope 
Farms, Woerden, The Netherlands) for 16 weeks with free access to water to induce 
insulin resistance
26
. All animal experiments were approved by the Animal Ethics 
Committee from the Leiden University Medical Center, Leiden, The Netherlands. 
 
Drugs. Obinepitide and TM30339 were supplied by 7TM Pharma.  These peptide 
analogues of pancreatic polypeptide were synthesized by solid phase peptide synthesis 
(SPPS) and purified by reversed phase high performance liquid chromatography. The 
peptides were dissolved in sterile 0.9% saline for injection and the solution pH adjusted to 
approximately pH 7.4 before being filtered through a 0.22 µm filter. 
 
Treatment. Mice were injected subcutaneously (sc) with phosphate buffered saline (PBS) 
twice daily (BID) for 11 days for habituation to daily injections. Thereafter, at 12 weeks of 
high-fat-feeding, the mice were divided into 2 x 5 groups. The groups were matched in 
fasting condition for body weight and plasma glucose levels for clamp experiments and 
body weight and plasma TG levels for VLDL production experiments (period of fasting was 
16 hours for clamp study and 4 hours for VLDL study). Each group received sc injections of 
Obinepitide BID (0.3 or 3.0 mg/kg), TM30339 once daily (OD) (0.3 mg/kg or 3.0 mg/kg), or 
saline BID for 4 weeks. The first dose was given at the beginning of the light period and the 
second dose directly before the lights went out. TM30339 was administered at the end of 
the light period. Mice receiving TM30339 also received vehicle on the first dosing occasion 
to mirror vehicle control. Before, after 2 weeks, and by the end of treatment, body weight, 
plasma glucose, insulin, free fatty acids (FFA), and TG concentrations were determined in 
fasting condition. On the day of study, mice received a last sc dosing of Obinepitide (0.3 or 
3.0 mg/kg), TM30339 (0.3 or 3.0 mg/kg), or saline 20 min prior to the experiments. 
 
Hyperinsulinemic euglycemic clamp. Mice had free access to high fat food and water until 
16 hours prior to the clamp (i.e. 17.00h the day before the clamp). Hyperinsulinemic 
euglycemic clamps were performed under 6.25 mg/kg acepromazine (Alfasan, Woerden, 
The Netherlands), 6.25 mg/kg midazolam (Roche, Mijdrecht, The Netherlands), and 0.3125 
mg/kg fentanyl (Janssen-Cilag, Tilburg, The Netherlands) anesthesia to quantify glucose 
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and glycerol turnover. First, basal rates of glucose and glycerol turnover were determined 
by giving a primed (p) continuous (c) intravenous (iv) infusion of [1-
14
C]-glucose (p: 0.2 µCi; 
c: 0.3 µCi/h, Amersham, Little Chalfont, U.K.) and [1-(3)-
3
H]-glycerol (p: 0.6 µCi; c: 0.9 
µCi/h, Amersham) for 60 minutes. Subsequently, insulin (Actrapid, Novo Nordisk, 
Denmark) was administered in a primed (4.5 mU) continuous (6.8 mU/h) iv infusion for 90 
minutes to attain steady state circulating insulin levels of ~4 ng/ml. A variable iv infusion 
of a 12.5% D-glucose solution was used to maintain euglycemia, as determined at 10 min 
intervals via tail bleeding (< 3 µl, Accu-chek, Sensor Comfort, Roche Diagnostics GmbH, 
Mannheim, Germany). Blood samples (60 µl) were taken via tail bleeding during the basal 
period (after 50 and 60 min) and during the clamp period (20 and 10 minutes prior to- and 
at the end of the clamp) to determine the plasma concentration of glucose, glycerol, FFA, 




H]-glycerol specific activities. At the end 
of the clamp, VLDL-TG production was quantified.  
 
VLDL-production. Basal VLDL production experiments were performed after a 4 hour fast 
(09.00-13.00h) and under 6.25 mg/kg acepromazine (Alfasan), 6.25 mg/kg midazolam 
(Roche), and 0.3125 mg/kg fentanyl (Janssen-Cilag) anesthesia. Mice received an iv 
injection of 100 µl PBS containing 150 µCi Tran
35
S label (GE Healthcare, Little Chalfont, 
U.K.) to label newly produced apoB. After 10 minutes, the animals received a sc dosing of 
Obinepitide (0.3 or 3.0 mg/kg), TM30339 (0.3 or 3.0 mg/kg), or saline. Twenty minutes 
thereafter, mice received a 15% (by volume) iv injection of tyloxapol (500 mg/kg body 
weight; Triton WR-1339, Sigma-Aldrich Corp., St. Louis, MO, US) to prevent systemic 
lipolysis of newly secreted hepatic VLDL-TG. Blood samples were taken before (time point 
0) and 15, 30, 60, and 90 min after tyloxapol injection. Thirty minutes after the last 
sampling, mice were sacrificed by cervical dislocation and exsanguinated via the retro-
orbital plexus.  
 Hyperinsulinemic VLDL-TG production was determined during continuous insulin 
infusion (6.8 mU/h) directly after the clamp study. Mice received a 15% (by volume) iv 
injection of tyloxapol (500 mg/kg body weight; Triton WR-1339, Sigma). Blood samples 
were taken before (time point 0) and 10, 20, 40, and 60 min after tyloxapol injection. After 
the last sampling, mice were sacrificed 
 
DEXA scan. Body composition was measured by dual-energy X-ray absorptiometry (DEXA) 
using the Norland pDEXA Sabre X-Ray Bone Densitometer (Norland, Hampshire, UK). 
During measuring, mice were anesthetized with a mixture of 6.25 mg/kg acepromazine 





Analytical procedures. Commercially available kits were used to determine plasma levels 
of glucose, FFA, TG (Instruchemie, Delfzijl, The Netherlands), and free glycerol (Sigma). 
Plasma insulin concentration was measured by ELISA (Crystal Chem. Inc., Downers Grove, 




H]-glycerol were determined in 8 µl 
plasma and in supernatants after trichloroacetic acid (20%) precipitation and water 
evaporation to eliminate tritiated water. VLDL was quantitatively isolated from plasma 
after density gradient ultracentrifugation at d<1.006 g/ml by aspiration. VLDL-apoB was 




Calculations. Turnover rates of glucose (µmol/min/kg) were calculated in basal and 
hyperinsulinemic conditions as the rate of tracer infusion (dpm/min) divided by the 




H]-glycerol (dpm/µmol). The ratio 
was corrected for body weight. Endogenous glucose production (EGP) was calculated as 
the difference between glucose disappearance and the infusion rate of glucose. Hepatic 
VLDL-TG production rates (µmol/h/kg) were calculated from the linear increase in plasma 
TG concentrations in time. 
 
Statistical analysis. Statistical analysis was performed using SPSS (version 16.0; SPSS Inc., 
Chicago, IL, USA). Differences between groups were determined with the Kruskal–Wallis 
non-parametric test for k independent samples. When significant differences were found, 
the Mann–Whitney non-parametric test was used as a follow-up test to determine 
differences between two independent groups. A p-value of less than 0.05 was considered 
statistically significant. Data are presented as mean ± SD. 
 
Results  
Body weight and DEXA scan. 3.0 mg/kg Obinepitide and both doses of TM30339 
significantly reduced body weight (figure 1). The decrease was most prominent during the 
first week of treatment. However, the difference with control animals remained till the 
end of the treatment period. Body weight reduction was fully accounted for by a 
reduction in fat mass, as shown by DEXA scan analysis (figure 2).  
 
Glucose metabolism 
Body weight and plasma parameters. Fasting body weights, plasma glucose, and insulin 
concentrations before and during treatment and in hyperinsulinemic conditions are shown 
in table 1. Chronic administration of 3.0 mg/kg Obinepitide and both doses of TM30339 
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reduced fasting plasma glucose levels. Basal plasma insulin levels were not affected by any 
of the treatments.  
 
 
Figure 1. Non-fasted bodyweight of mice after treatment 
with Obinepitide (Ob) (0.3 or 3.0 mg/kg), TM30339 (TM) 
(0.3 or 3.0 mg/kg), or vehicle for 4 weeks. Values 
represent mean ± SD for at least 21 mice per group. *p 
<0.05 vs. control. **p <0.01 vs. control. 
Figure 2. Body composition of mice after treatment with 
Obinepitide (Ob) (0.3 or 3.0 mg/kg), TM30339 (TM) (0.3 or 
3.0 mg/kg), or vehicle for 4 weeks. Values represent mean 
± SD for at least 6 mice per group. *p <0.05 vs. control.  
 
Hyperinsulinemic euglycemic clamp. Basal glucose turnover, glucose disposal and EGP in 
hyperinsulinemic conditions after 4 weeks of treatment are shown in table 2. In basal 
conditions, there was no difference in glucose turnover between groups. Chronic 
administration of 3.0 mg/kg Obinepitide and both doses of TM30339 increased the rate of 
glucose infusion necessary to maintain euglycemia during insulin administration, 
indicating that both drugs enhanced whole body insulin sensitivity (figure 3).  
 Glucose disposal during insulin infusion was significantly increased in 3.0 mg/kg 
Obinepitide and 3.0 mg/kg TM30339 treated mice (table 2). If expressed as a percentage 
from baseline values, also 0.3 mg/kg TM30339 treatment increased insulin’s action to 
stimulate glucose disposal (figure 4). Glucose production during insulin infusion was 
significantly decreased in TM30339 treated animals (table 2). If expressed as a percentage 
from baseline values, the highest dose of Obinepitide also reinforced the capacity of 
insulin to suppress EGP (figure 5). The lowest dose of Obinepitide did not significantly 








Table 1. Plasma parameters in basal (fasting) condition and during hyperinsulinemia, before and during chronic treatment with 
Obinepitide (BID) (0.3 or 3.0 mg/kg), TM30339 (OD) (0.3 or 3.0 mg/kg), or control. Values represent mean ± SD for at least 10 




           Obinepitide (BID)            TM30339 (OD) 
0.3 mg/kg 3.0 mg/kg 0.3 mg/kg 3.0 mg/kg 
Body weight 
(g) 
Start treatment 31.2 ± 2.5 30.9 ± 2.1 31.3 ± 2.5 31.1 ± 2.9 31.3  ± 3.0 
2 wks treatment 31.3 ± 2.2 30.1 ± 1.9 29.5 ± 1.0 28.8 ± 1.8** 28.2 ± 1.4** 
4 wks treatment 31.5 ± 2.3 30.3 ± 1.5 28.6  ± 0.6** 28.6 ± 1.5** 27.9 ± 1.2** 
Hyperinsulinemic - - - - - 
Glucose 
(mmol/l) 
Start treatment 6.9 ± 1.2 6.7 ± 0.6 6.7 ± 1.0 7.0 ± 1.0 6.5 ± 0.9 
2 wks treatment 6.8 ± 1.1 6.3 ± 0.8 5.0 ± 1.8** 5.6 ± 0.9** 5.1 ± 1.2** 
4 wks treatment 6.0 ± 1.3 6.0 ± 1.5 5.1 ± 0.7** 5.0 ± 0.6** 4.8 ± 0.6** 
Hyperinsulinemic 5.9 ± 1.3 6.2 ± 1.1 5.4 ± 0.8 5.1 ± 0.7 4.7 ± 0.6 
Insulin  
(ng/ml) 
Start treatment 0.5 ± 0.3 0.5 ± 0.2 0.4 ± 0.2 0.5 ± 0.2 0.5 ± 0.3 
2 wks treatment 0.5 ± 0.2 0.5 ± 0.2 0.3 ± 0.2 0.5 ± 0.3 0.3 ± 0.2 
4 wks treatment 0.7 ± 0.3 0.6 ± 0.3 0.4 ± 0.2 0.6 ± 0.4 0.4 ± 0.2 
Hyperinsulinemic 3.9 ± 1.1 4.1 ± 1.1 3.5 ± 0.7 3.6 ± 1.0 3.4 ± 0.9 
 Start treatment 0.9 ± 0.2 0.8 ± 0.2 1.0 ± 0.3 0.9 ± 0.2 0.9 ± 0.2 
FFA  
(mmol/l) 
2 wks treatment 0.9 ± 0.2 0.9 ± 0.2 1.0 ± 0.2 0.9 ± 0.2 0.8 ± 0.3 
4 wks treatment 0.8 ± 0.2 0.7 ± 0.2 0.7 ± 0.2 0.8 ± 0.3 0.7 ± 0.2 










Figure 3. Glucose infusion rate (GIR) during a 
hyperinsulinemic euglycemic clamp in mice after 
treatment with Obinepitide (Ob) (0.3 or 3.0 mg/kg), 
TM30339 (TM) (0.3 or 3.0 mg/kg), or control for 4 weeks. 
Values represent mean ± SD for at least 10 mice per 
group. **p <0.01 vs. control. 
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Figure 4. Stimulation of glucose disposal during a 
hyperinsulinemic euglycemic clamp in mice after 
treatment with Obinepitide (Ob) (0.3 or 3.0 mg/kg), 
TM30339 (TM) (0.3 or 3.0 mg/kg), or control for 4 weeks. 
Values represent mean ± SD for at least 10 mice per 
group. *p <0.05 vs. control. **p <0.01 vs. control. 
Figure 5. Inhibition of endogenous glucose production 
(EGP) during a hyperinsulinemic euglycemic clamp in mice 
after treatment with Obinepitide (Ob) (0.3 or 3.0 mg/kg), 
TM30339 (TM) (0.3 or 3.0 mg/kg), or control for 4 weeks. 
Values represent mean ± SD for at least 10 mice per 
group. *p <0.05 vs. control. **p <0.01 vs. control. 
 
 
Table 2. Glucose turnover in basal and hyperinsulinemic conditions in mice that received treatment for 4 weeks with Obinepitide 
(BID) (0.3 or 3.0 mg/kg), TM30339 (OD) (0.3 or 3.0 mg/kg), or control. Values represent mean ± SD for at least 10 mice per group. 




              Obinepitide (BID)               TM30339 (OD) 













27.9 ± 12.5 31.6 ± 15.7 19.8 ± 11.6 14.1 ± 7.6** 10.9 ± 8.3** 
 
VLDL metabolism 
Neither drug affected VLDL-apoB or VLDL-TG production rate in basal (fasting) conditions 
(table 3). Remarkably, both drugs appeared to elevate plasma TG concentrations in basal 
condition, where the increase was statistically significant (compared to control) for the 
highest dose of each drug. During insulin infusion, plasma TG concentrations rose more 
slowly after tyloxapol in mice that received chronic injections of 3.0 mg/kg TM30339 






Table 3. Bodyweight, plasma TG levels and VLDL production rate in basal (fasting) condition and during hyperinsulinemia before 
and during chronic treatment with Obinepitide (BID) (0.3 or 3.0 mg/kg), TM30339 (OD) (0.3 or 3.0 mg/kg), or control. Values 
represent mean ± SD for at least 7 mice per group. *p <0.05 vs. control. **p<0.01 vs. control. 
#




           Obinepitide (BID)            TM30339 (OD) 
0.3 mg/kg 3.0 mg/kg 0.3 mg/kg 3.0 mg/kg 
Body weight 
(g) 
Start treatment 31.0 ± 2.2 31.7 ± 3.9 31.0 ± 2.4 31.4 ± 3.8 31.4  ± 4.4 
2 wks treatment 31.4 ± 2.2 31.5 ± 3.2 30.1 ± 1.8 29.8 ± 2.9 28.8 ± 2.9 
4 wks treatment 32.4 ± 2.1 32.2 ± 3.5 29.8  ± 1.6 30.1 ± 3.1 29.7 ± 3.0 
TG  
(mmol/l) 
Start treatment 0.54 ± 0.11 0.53 ± 0.10 0.49 ± 0.12 0.50 ± 0.13 0.46  ± 0.11 
2 wks treatment 0.62 ± 0.07 0.61 ± 0.07 0.58 ± 0.08 0.55 ± 0.16 0.40 ± 0.08 














167 ± 29 169 ± 48 159 ± 10 172 ± 27 134 ± 17** 
 
Lipolysis 
Obinepitide or TM30339 did not affect lipolysis (glycerol Ra) (figure 7) or circulating FFA 
concentrations in basal (fasting) conditions (table 1). Although insulin infusion reduced 
glycerol turnover significantly in the 3.0 mg/kg Obinepitide and TM30339 groups, insulin’s 
capacity to suppress glycerol turnover (expressed as percentage of baseline values) was 
not affected by any of the interventions (data not shown). Also, the decline of plasma FFA 
concentrations induced by insulin was not affected by either drug (table 1). 
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Figure 6. Triglyceride (TG) concentration after tyloxapol 
injection in hyperinsulinemic conditions in mice after 
treatment with Obinepitide (0.3 or 3.0 mg/kg), TM30339 
(0.3 or 3.0 mg/kg), or vehicle for 4 weeks. Values 
represent mean ± SD for at least 10 mice per group. **p 
<0.01 vs. control. 
Figure 7. Glycerol turnover during a hyperinsulinemic 
euglycemic clamp in mice after treatment with 
Obinepitide (0.3 or 3.0 mg/kg), TM30339 (0.3 or 3.0 
mg/kg), or vehicle for 4 weeks. Values represent mean ± 
SD for at least 10 mice per group. *p <0.05 vs. basal. **p 
<0.01 vs. basal. 
 
Discussion 
This study shows that Obinepitide and TM30339 may be useful tools to improve glucose 
metabolism in diet-induced insulin resistant C57Bl/6J mice. In particular, chronic 
administration of Obinepitide (3.0 mg/kg) and TM30339 (0.3 and 3.0 mg/kg) reduced 
fasting plasma glucose in these animals. Moreover, chronic treatment with these drugs 
clearly enhanced whole body insulin sensitivity. Both compounds can reinforce insulin’s 
capacity to stimulate glucose disposal and inhibit glucose production. In addition, insulin’s 
capacity to inhibit VLDL-TG production was reinforced by chronic treatment with 3.0 
mg/kg TM30339. 
The beneficial effects on body weight corroborate the results of previous pre-
clinical studies investigating the anti-obesity potential of Obinepitide and TM30339
20, 21
. 
All weight was lost in the first week of treatment, which is consistent with earlier findings 
documenting a transient effect on food intake and body weight of chronic PYY3-36 
treatment
11, 27
. Clearly, in time, the body compensates via yet unknown mechanisms to 
restore energy homeostasis. However, despite the loss of this acute effect, body weight 
remained lower during treatment with either drug. The decline of body weight was fully 
accounted for by a reduction of fat mass. Neither Obinepitide nor TM30339 affected 
lipolysis or insulin’s capacity to suppress this process and, accordingly, neither drug 




attributed to a lipolytic effect of the drugs. Alternatively, the decline of fat mass may have 
been the result of a shift in the balance of fuel use in favor of fat oxidation
11, 17
.  
Besides affecting body weight, both drugs clearly ameliorated insulin resistance. 
In particular, Obinepitide enhanced insulin mediated glucose disposal, an observation that 
is in line with previous findings of chronic PYY3-36 treatment
16, 17
. Interestingly, our findings 
also show that agonism of Y4R reinforces insulin’s ability to promote glucose disposal, 
indicating a novel role for this receptor. Moreover, both drugs reinforced insulin action to 
inhibit EGP. Previous studies showed that activation of Y2 receptors by PYY3-36 reinforces 
insulin mediated glucose disposal, but not its capacity to suppress EGP. Therefore, the 
impact of Obinepitide on EPG might be mediated by the Y4R. In this respect, it is 
interesting to note that PP infusion in patients with chronic pancreatitis, a condition 
accompanied by decreased PP levels, ameliorates insulin resistance of EGP
28
.  
The mechanism underlying the effects of both compounds on insulin sensitivity of 
glucose metabolism remains to be established. A single injection of both drugs did not 
affect glucose metabolism in the same experimental context (data not shown). It is 
conceivable that the drugs work via their impact on food intake and/or body weight
29
. 
However, chronic PYY3-36 administration enhances insulin-mediated glucose disposal via a 
mechanism that is independent of food intake and body weight
17
. Whatever the 
mechanism, and highly significant, the present data suggest that chronic treatment with 
Obinepitide or TM30339 has beneficial metabolic effects in insulin resistant DIO mice, 
which holds promise for their potential as tools to treat obesity and type 2 diabetes in 
humans. 
These drugs do not appear to modulate VLDL metabolism in basal conditions.  
However, insulin’s capacity to inhibit VLDL-TG production was reinforced by chronic 
treatment with 3.0 mg/kg TM30339, suggesting that the drug may be able to improve 
postprandial control of TG production. It is rather surprising that only the highest dose of 
TM30339 was effective, since the lower dose of TM30339 and 3.0 mg/kg Obinepitide have 
a similar impact on body weight and glucose metabolism. The mechanism underlying the 
capacity of TM30339 to reinforce insulin action to reduce VLDL-TG production needs to be 
clarified in more detail.  
Unexpectedly, both Obinepitide and TM30339 increased fasting plasma TG levels 
after 4 weeks of treatment. In view of the fact that VLDL-TG production in basal condition 
was not affected by either one of the drugs, this observation suggests that both 
compounds hamper clearance of VLDL particles from the circulation. Since 
hypertriglyceridemia is a cardiovascular risk factor, this feature of the drugs is worrisome 
if confirmed in future (clinical) experiments. It is important to note that comparison 
between plasma TG levels at 2 vs. 4 weeks of intervention is difficult, since the timing of 
Effects of Obinepitide and TM30339 on insulin sensitivity 
97 
 
drug administration was somewhat different. At 2 weeks, the last injection was given 4 
hours before blood sampling, compared to 20 minutes before blood sampling during the 
VLDL production experiment. The latter may indicate that Obinepitide and TM30339 
acutely increased plasma TG levels. Increased TG levels have been observed previously in 
chow-fed transgenic mice over-expressing PYY
14
. When these mice were put on a high-fat 
diet, TG levels decreased to the level observed in control animals. PYY over-expressing 
mice on an ob/ob background have decreased plasma TG levels compared to controls. 
These observations suggest that the metabolic background modulates the impact of Y2R 
activation (Y2R is the primary receptor of PYY3-36) on TG levels. Therefore, it is conceivable 
that Obinepitide and/or TM30339 impact on plasma TG concentrations in obese animal 
models differently than in the animal model used here (and perhaps obese humans as 
well).  
 In conclusion, the current study indicates that Obinepitide and TM30339 reduce 
body weight and ameliorate insulin resistance of glucose metabolism in C57Bl/6J mice 
maintained on a high fat diet. The drugs did not impact on lipolysis, and only the highest 
dose of TM30339 reinforced the capacity of insulin to inhibit VLDL-TG production. These 
data hold promise for the potential of these drugs as tools to treat obesity and type 2 
diabetes mellitus in humans.  
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Type 2 diabetes mellitus has now become a global epidemic with increasing number of 
patients every year according to figures of the World Health Organization
1
. It is a disorder 
characterized by high blood glucose concentrations in the context of insulin resistance and 
relative insulin deficiency. While it is often initially managed by increasing exercise and 
dietary modification, medications are typically needed as the disease progresses. The past 
decade hormones from the gastrointestinal tract have gained much interest as potential 
new therapeutic drug targets in the battle against type 2 diabetes. Gut peptides play an 
important role in regulating food intake and energy homeostasis. In addition, via 
overlapping pathways, they are able to impact on insulin sensitivity. Therefore, and with 
the increasing incidence of obesity, which can lead to several chronic diseases, including 
type 2 diabetes, these peptides became even more interesting for therapeutic 
interventions. Since the physical properties (mainly their short-half lives) of native gut 
hormones do not ultimately allow for therapy, pharmaceutical companies are now 
developing peptide analogues with improved qualities. The present thesis focuses on 
modulation of insulin sensitivity of glucose and lipid metabolism by different gut 
hormones or their analogues. 
 In the current thesis all experiments were performed in wild-type male C57Bl/6 
mice, except for chapter 4, in which APOE*3-Leiden mice were used. The C57Bl/6 mice are 
very susceptible to diet-induced insulin resistance, and therefore a suitable model to study 
modulation of insulin sensitivity by peptide/drug interventions. Insulin sensitivity was 
measured by the hyperinsulinemic euglycemic clamp technique, considered the golden 
standard method for quantification of insulin action. VLDL production was determined 
after blocking lipolysis.  
  
Recent findings indicate that gut hormones, like PYY3-36 and GLP-1, target the brain to 
regulate food intake, and in addition, impact on insulin sensitivity. Another gut hormone, 
OXM, has also been shown to affect food intake and appetite. Its effects on glucose 
metabolism are rather unexplored. In chapter 2 we demonstrate that OXM beneficially 
affects glucose metabolism in diet-induced insulin-resistant C57Bl/6 mice. These effects 
were found at circulating insulin levels that were more than double during insulin infusion 
in OXM-treated mice, complicating the interpretation of the data. Indeed, per unit of 
ambient insulin concentration, glucose uptake and EGP were not different in OXM and 
placebo-treated animals. The exact mechanism via which OXM affects glucose metabolism 
remains to be elucidated. OXM is co-released with GLP-1 from intestinal L-cells into the 
blood in response to food ingestion in amounts proportional to caloric content. After 
being released, it has to bind its receptor to initiate a reaction; however no unique 
receptor for OXM has been identified yet. Since the actions of OXM resemble those 
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described for GLP-1 (it also inhibits meal-stimulated gastric acid secretion and food 
intake), OXM is believed to act via the GLP-1 receptor, although it also, with a much lower 
affinity, can bind the glucagon receptor (Gcgr). The anorectic actions of OXM require the 
GLP-1 receptor only, as centrally administered OXM  inhibits food intake in mice that lack 
the Gcgr, but the anorectic effects of OXM are completely absent in GLP-1R-/- mice
2
. 
Furthermore, OXM exerts its effects on the islet β-cell in a GLP-1R dependent manner; it 
stimulates glucose-dependent insulin secretion and activates cell survival pathways 
leading to reduced β-cell apoptosis
3
. In addition, the amelioration of glucose tolerance we 
found was confirmed to be mediated via the GLP-1 receptor 
3
. Although the precise 
mechanisms utilized by OXM for transduction of various biological actions remain unclear, 
a few studies demonstrate a dissociation between actions of OXM and those of GLP-1
4, 5
. 
Therefore, the importance of OXM as a biologically active peptide would be greatly 
strengthened by the identification of a separate OXM receptor, or by studies employing 
specific OXM antagonists or immunoneutralizing antisera that block actions of OXM but 
not glucagon or GLP-1. However, the fact that OXM can improve glucose tolerance in high 
fat fed, insulin resistant mice indicates that this peptide (or any novel peptidomimetic) 
may be useful in the treatment of obesity and type 2 diabetes, like other proglucagon 
derived peptides. Unexpectedly, OXM enhanced glucose production in the basal condition, 
probably by virtue of its capacity to activate the glucagon (or a yet unidentified OXM) 
receptor in the liver. This augmented increase in basal glucose turnover by OXM has not 
been described before for GLP-1. Indeed, in chapter 3, the GLP-1 analogue CNTO736 even 
decreases glucose turnover in basal conditions. Obviously, stimulation of glucose 
production is an undesirable quality of drugs used to treat insulin resistance that requires 
careful evaluation. At the end of the day, if it turns out to be a consistent metabolic effect 
of treatment with OXM (mimetics), excessive glucose production clearly limits the clinical 
applicability of this peptide.   
 The actions of native GLP-1 (it enhances glucose-stimulated insulin secretion, 
improves blood glucose profiles of type 2 diabetes patients, reduces body weight and food 
intake, and slows gastric emptying) were the main reasons for the physiological and 
pharmacological interest in this peptide. Clinical trials have shown that exendin-4, a 
potent GLP-1 receptor agonist, is useful in the regulation of glucose homeostasis in people 
with type 2 diabetes mellitus. A disadvantage of Byetta, the marketing name of Exenatide 
(the synthetic version of exendin-4), is the twice daily injection within 60 minutes of food 
intake. Therefore, the development of GLP-1 analogues continues. CNTO736 is one of 
those novel analogues. It retains many activities of native GLP-1 yet has a significantly 
enhanced pharmacokinetic profile. Moreover, it has a longer half-life than exendin-4 in 




chapter 3 the effects of this novel GLP-1 analogue were investigated with regards to its 
impact on insulin sensitivity of glucose and lipid metabolism. Our data corroborate earlier 
reports indicating that GLP-1 and its analogues in the long run ameliorate whole body 
insulin resistance in obese animal models and in T2DM patients
6-9
. They further extend 
our knowledge of the precise actions of GLP-1 analogues on distinct components of 
glucose flux in insulin resistant animals, inasmuch as they show that these compounds 
acutely reinforce insulin’s ability to promote glucose disposal and boost insulin action on 
both glucose uptake and production in the long term. Since insulin resistance is a complex 
disease and is associated with obesity and cardiac disease, drug intervention that can 
handle multiple aspects of the disease are preferable. Therefore, the observations that 
chronic CNTO736 treatment decreases body weight and inhibits VLDL-TG synthesis are 
very promising. Since the C57Bl/6 mice are not a suitable model for studying lipid 
metabolism, we further explored the inhibitory effect of GLP-1M (the latest version of the 
CNTO molecule) on VLDL-TG production in chapter 4 in APOE*3-Leiden mice. APOE*3-
Leiden mice express the human APOE*3-Leiden gene, resulting in a lipoprotein profile 
reminiscent of that of patients with dysbetalipoproteinemia, marked by elevated plasma 
cholesterol and triglyceride levels that are mainly confined to the VLDL/LDL-sized 
lipoprotein fraction. In contrast to other mice, APOE*3-Leiden transgenics respond to 
various hypolipidemic drugs in a similar way as humans and are therefore considered a 
“human-like” animal model for studies evaluating the impact of drugs on hyperlipidemia
10, 
11
. Chronic administration of GLP-1M in high-fat-fed APOE*3-Leiden mice clearly inhibited 
VLDL-TG production. Moreover, chronic administration of the drug decreased total 
cholesterol levels and increased HDL in the same experimental context. Our data suggest 
that GLP-1M may have powerful anti-atherogenic properties in insulin resistant subjects. 
Atherosclerosis is driven by increased (VLDL) cholesterol and TG levels, often accompanied 
by low circulating HDL concentrations. HDL particles are anti-atherogenic, partly because 
of their role in reverse cholesterol transport, but also because of their anti-oxidative, anti-
inflammatory, anti-thrombotic, and anti-apoptotic properties
12-14
. Therefore, the 
reduction of plasma cholesterol concentration by GLP-1M as well as its capacity to 
increase HDL cholesterol levels holds promise as pharmacological tool to prevent 
atherosclerosis in high risk metabolic conditions. However, the pathophysiological 
consequence of the capacity of GLP-1M to inhibit VLDL secretion is uncertain, because 
circulating TG levels were not affected, perhaps as a result of a diminished clearance of TG 
from plasma.  
Notably, although exendin-4 did impact on insulin sensitivity to a similar extent as 
CNTO736 in chapter 3, it did not impact on VLDL-synthesis in our experimental set-up. 
This suggests that GLP-1M may have compound-specific effects on lipid metabolism that 
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potentially reinforce its capacity to prevent macrovascular disease in high fat-fed mice 
(and humans). On the other hand, it might be related to the serum half-life of GLP-1M, 
which is considerably longer than exendin-4. This issue needs to be clarified before a firm 
conclusion can be drawn on the effects of GLP-1M on VLDL metabolism.  
  
All peripheral signals from the gastrointestinal tract convey metabolic information to the 
brain. The main structures involved in the control of glucose homeostasis are the 
hypothalamus and brainstem. The hypothalamus is the first integration centre of 
hormonal information. Specifically, the arcuate nucleus (ARC), located in the mediobasal 
hypothalamus, contains neurons sensitive to both hormones (ghrelin, leptin, GLP-1) and 
nutrients (glucose, fatty acids). Downstream targets of the ARC include the paraventricular 
and dorsomedial hypothalamus nuclei. Other projections of the ARC target the 
medialpreoptic area, lateral hypothalamus and ventromedian area. Finally, the structure 
of the limbic system and cortex also interact with the hypothalamus. It is currently 
unknown to what extent the (metabolic) effects of circulating GLP-1 are mediated by 
central GLP-1 receptors. In chapter 5, we show that GLP-1 treatment ameliorates insulin 
resistance of glucose metabolism in high-fat-fed mice in part via activation of central GLP-
1 receptors. The neuronal circuits that are activated by peripheral administered GLP-1 and 
mediate its metabolic effects remain to be identified. 
 One possibility is that GLP-1 in the hypothalamus modulates the neuropeptide Y 
(NPY) pathway. It has been shown previously that intracerebroventricular administration 
of GLP-1 completely prevents the orexigenic effects of NPY, suggesting that GLP-1 acts by 
blocking NPY transmission to inhibit food consumption
15
. Intracerebroventricular 
administration of NPY acutely impairs insulin’s ability to suppress endogenous glucose 
production
16
. In addition, animal models of obesity and type 2 diabetes (including diet-
induced obesity) are marked by elevated NPY expression in hypothalamic nuclei
17, 18
. For 
these reasons, it is conceivable that these exceedingly active NPY neurons are involved in 
the pathophysiology of enhanced endogenous glucose production in the face of 
hyperinsulinemia in these models (and obese humans). GLP-1 has been reported to 
reduce hypothalamic NPY neuronal activity
19
. Therefore, chronic administration of GLP-1 
or any of its analogues may have antagonized NPY-induced insulin resistance to explain 
the findings presented here. 
 The hypothalamus is, however, not solely responsible for the integration of 
peripheral information originating from the gut. The brainstem, in addition to interacting 
with hypothalamic circuits, also plays a principal role in the regulation of energy 
homeostasis. Located in the brainstem, the nucleus of the solitary tract (NTS) receives 




activate neurons in the NTS in the brain stem via afferent vagal inputs to modulate glucose 
metabolism. GLP-1 evokes vagal afferent nerve activity to initiate a hepatopancreatic 
reflex that is critically involved in the control of insulin release
20
. It is conceivable that 
vagal afferent output in this context is not limited to the pancreas also but affects liver 
and other visceral organs to modulate glucose production. Moreover, vagal ablation 
attenuates the anorexigenic effects of peripheral GLP-1 administration
21
. In analogy, 
activation of vagal afferents by GLP-1 may affect glucose metabolism. Besides affecting 
afferent fibres, peripheral GLP-1 may also impact directly on the brainstem. Like the ARC, 
the NTS is in close anatomical proximity to a circumventricular organ with an incomplete 
blood-brain-barrier - the area postrema (AP) - and is therefore in an ideal position to 
respond to peripheral circulating signals, such as GLP-1. Indeed, administration of GLP-1 
results in a significant increase in signal intensity in the AP of fasted mice, reflecting an 
increase in neuronal activity within the brainstem
22
. 
 However, despite the compelling evidence of the importance of the gut-brain axis 
in the control of glucose homeostasis, it remains possible that GLP-1 acts directly on the 
liver and other peripheral tissues via a structurally and functionally distinct GLP-1R. 
Indeed, GLP-1 was reported to have insulin-like actions in liver and skeletal muscle, which 




Finally, in chapter 6, the potential of two novel developed analogues, Obinepitide and 
TM30339, was explored. The results show that chronic treatment with these drugs 
beneficially impacts on insulin resistance in high-fat-fed mice, with respect to insulin 
mediated glucose disposal and production. Both compounds, in analogy with its property 
as anti-obesity drugs, also reduced body weight (by decreasing total fat mass) in our 
experimental set-up. Since insulin sensitivity and weight loss are strongly correlated
25
, the 
effect on the later might be the underlying cause for the reduction in insulin resistance. 
Pair-feeding studies may provide the answer. Regardless of the mechanism, and highly 
significant, our results indicate that the metabolic effects of Obinepitide and TM30339 do 
not vanish during chronic treatment, making them valuable drugs to treat both obesity 
and insulin resistance.   
  
In conclusion, we have shown a variety of gut hormones or its peptidomimetics to 
beneficially impact on glucose metabolism. However, our animal models still raise 
questions, which need to be clarified in more detail, before to the drugs can be used in the 
clinical setting. Long-term treatment may also have side-effects, related to gastric 
emptying and nausea, which have been reported before for GLP-1 and related molecules. 
Also, in response to post-marketing reports of acute pancreatitis in patients using 
Summary and conclusions 
107 
 
Exenatide, the U.S. Food and Drug Administration (FDA) added a warning to the labeling of 
Byetta in 2007. In August 2008, four additional deaths from pancreatitis in users of 
Exenatide were reported to the FDA; while no definite relationship had been established, 
the FDA was reportedly considering additional changes to the labeling of this drug. 
 Over the past decade a growing amount of evidence indicates that the gut-brain 
axis is a key player in the control of glucose homeostasis. Peptides such as GLP-1 have 
emerged as key factors able to convey metabolic information to the brain and also to 
modulate endogenous glucose production and disposal. Elucidating more precisely the 
molecular events in the brain that underlie the effects of these hormones could lead to 
the identification of new (or improved) therapeutic agents. 
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Type 2 diabetes mellitus (suikerziekte) is aan het uitgroeien tot een wereldwijde epidemie 
met een toenemend aantal patiënten elk jaar volgens cijfers van de 
Wereldgezondheidsorganisatie
1
. Het is een aandoening gekarakteriseerd door een hoge 
bloedsuikerspiegel (hyperglycemie) in combinatie met ongevoeligheid voor insuline 
(insulineresistentie) en een betrekkelijk insulinetekort. Daar waar de ziekte in het 
beginstadium onder controle kan worden gehouden door meer beweging en een wijziging 
van het voedselpatroon, is medicatie nodig wanneer de ziekte verergert. Het afgelopen 
decennium hebben hormonen van het maag-darmstelsel veel interesse geworven om 
mogelijk als nieuwe therapeutische medicijnen te dienen in the strijd tegen type 2 
diabetes. Darmhormonen spelen een belangrijke rol in het reguleren van de 
voedselinname en de energiehuishouding. Daarnaast, kunnen ze, via overlappende paden, 
invloed uitoefenen op de insulinegevoeligheid. Om deze redenen, en met het oog op het 
toegenomen aantal gevallen met obesitas (zwaarlijvigheid), wat tot verscheidene 
chronische ziektes kan leiden, waaronder type 2 diabetes, werden deze eiwitten nog 
interessanter voor therapeutische interventies. Omdat de fysische eigenschappen (in het 
bijzonder hun korte halfwaardetijden) van lichaamseigen darmhormonen vaak niet 
geschikt zijn om voor therapie te kunnen dienen, worden er nu door farmaceutische 
bedrijven analogen van deze eiwitten ontwikkeld met verbeterde kwaliteiten. Dit 
proefschrift richt zich op het beïnvloeden van de insulinegevoeligheid van de glucose- en 
vetstofwisseling door verschillende darmhormonen en hun analogen.  
 In dit proefschrift zijn alle experimenten uitgevoerd in mannelijke C57Bl/6 
muizen, behalve voor hoofdstuk 4, waarin de APOE*3-Leiden muis werd gebruikt. De 
C57Bl/6 muis is zeer gevoelig voor dieetgeïnduceerde insulineresistentie en daarom een 
geschikt model om de effecten op de insulinegevoeligheid na medicijntoediening te 
bestuderen. De mate van insulinegevoeligheid werd gemeten met de hyperinsulinemische 
euglycemische clamp techniek, welke beschouwd wordt als de gouden standaard voor het 
bepalen hiervan. De productie van VLDL (een deeltje dat vet uit de lever naar weefsels 
transporteert) werd bepaald na het blokkeren van de klaring van vet.  
  
Recente bevindingen laten zien dat darmhormonen, zoals peptideYY3-36 en glucagon-like 
peptide-1 (GLP-1), de voedselinname reguleren via de hersenen, en daarnaast ook, 
invloed uitoefenen op de insulinegevoeligheid. Van een ander darmhormoon, 
oxyntomoduline (OXM), is ook bekend dat het de voedselinname en het hongergevoel kan 
beïnvloeden. Echter, de effecten van OXM op de glucosestofwisseling zijn weinig 
onderzocht. In hoofdstuk 2 laten wij zien dat OXM de glucosestofwisseling positief kan 
beïnvloeden in dieetgeïnduceerde insuline resistente C57Bl/6 muizen. Deze effecten 
werden gevonden bij circulerende insulineconcentraties die meer dan verdubbeld waren 
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in OXM behandelde muizen vergeleken met de controle groep, wat de interpretatie van 
de data gecompliceerd maakt. Inderdaad, wanneer de glucose opname en productie 
gecorrigeerd werden voor de rondcirculerende insulineconcentratie, werd geen verschil 
gevonden tussen OXM en placebo behandelde dieren. Het exacte mechanisme hoe OXM 
de glucosestofwisseling beïnvloedt moet nog worden opgehelderd. OXM wordt samen 
met GLP-1 vrijgelaten in het bloed uit de zogenoemde L-cellen van de darm in reactie op 
voedselinname in hoeveelheden proportioneel aan de calorische hoeveelheid. Na te zijn 
vrijgekomen, moet OXM zijn receptor binden om een reactie te initiëren; echter tot op 
heden is er geen unieke OXM receptor gevonden. Omdat de acties van OXM veel gelijkenis 
tonen met hetgeen beschreven is voor GLP-1 (het remt maaltijdgestimuleerde 
maagzuursecretie en voedselinname), wordt aangenomen dat OXM via de GLP-1 receptor 
(GLP-1R) werkt, hoewel het ook, alleen met veel minder affiniteit, aan de glucagon 
receptor (Gcgr) kan binden. De anorectische acties van OXM vereisen alleen de GLP-1 
receptor, aangezien OXM, gegeven in het brein, de voedselinname remt in muizen die 
geen Gcgr hebben. De anorectische effecten van OXM waren volledig afwezig in muizen 
zonder GLP-1R
2
. Daarnaast oefent OXM zijn effecten op de β-cel van de alvleesklier uit op 
een GLP-1R afhankelijke manier; het stimuleert glucoseafhankelijk de insulinesecretie en 
activeert cel overlevingspaden die leiden tot een afname van sterfte van de β-cel
3
. Ook 
van de verbetering van de glucosetolerantie die wij vonden, werd bevestigd dat deze via 
de GLP-1R gestuurd wordt
3
. Hoewel het precieze mechanisme achter verscheidene 
biologische acties van OXM nog onduidelijk blijft, zijn er een aantal studies die laten zien 
dat er ook verschillen zijn tussen de acties van OXM en die van GLP-1
4, 5
. Daarom zal het 
belang van OXM als een biologisch actief eiwit flink versterkt worden door het 
identificeren van een eigen OXM receptor of door studies die gebruik maken van 
specifieke OXM antagonisten of immumoneutraliserende antisera die de werking van 
OXM, maar niet van glucagon of GLP-1, blokkeren. Echter, het feit dat OXM de 
glucosetolerantie in hoog vet gevoede insuline resistente muizen kan verbeteren, geeft 
aan dat dit eiwit (of elk nieuw ontwikkeld analoog) bruikbaar kan zijn in de behandeling 
van obesitas en type 2 diabetes, net als andere van proglucagon afkomstige eiwitten (o.a. 
GLP-1). Echter, geheel onverwacht, verhoogde OXM de glucose productie in nuchtere 
condities, waarschijnlijk middels zijn capaciteit om de Gcgr (of een nog ongeïdentificeerde 
OXM receptor) in de lever te activeren. Deze verhoging in glucose productie door OXM is 
niet beschreven voor GLP-1. In tegenstelling, in hoofdstuk 3, verlaagt de GLP-1 analoog 
CNTO736 zelfs de glucoseconcentratie in basale condities. Het is onmiskenbaar dat de 
stimulatie van de glucose productie een ongewenste eigenschap is van een medicijn 
bedoeld om insulineresistentie mee te behandelen en vraagt daarom zorgvuldig 




(analogen) behandeling is, dan limiteert overmatige glucose productie de klinische 
potentie van deze stof.  
 De eigenschappen van GLP-1 (het verhoogt de glucose-gestimuleerde insuline 
secretie, verbetert bloedglucose profielen van type 2 diabetes patiënten, vermindert 
lichaamsgewicht en voedselinname en vertraagt de maaglediging) waren de belangrijkste 
redenen voor de fysiologische en farmacologische belangstelling van dit eiwit. Klinische 
studies hebben aangetoond dat exendin-4, een van nature voorkomende GLP-1 analoog, 
zeer bruikbaar is bij de regulering van de glucosehuishouding in mensen met type 2 
diabetes mellitus. Een nadeel van Byetta, de merknaam van exenatide (de synthetische 
versie van exendin-4), is het tweemaal daags injecteren binnen 60 minuten van de 
voedselinname. Daarom gaat de ontwikkeling van GLP-1 analogen verder. CNTO736 is één 
van die nieuwe analogen. Het bezit de vele activiteiten van het oorspronkelijke GLP-1, 
echter heeft het een aanzienlijk verbeterd farmacokinetisch profiel. Bovendien heeft het 
een langere halfwaardetijd dan exendin-4 in muizen (15-20 uur vs ~2 uur) wat kan 
bijdragen aan minder injecties bij patiënten. In hoofdstuk 3 werden de effecten van deze 
nieuwe GLP-1-analoog onderzocht met betrekking tot het effect op de 
insulinegevoeligheid van de glucose- en vetstofwisseling. Onze data bevestigen eerdere 
rapporten waaruit blijkt dat GLP-1 en zijn analogen op de lange termijn insulineresistentie 
van het hele lichaam in obese diermodellen en in patiënten met type 2 diabetes 
verbeteren
6-9
. Verder breiden zij onze kennis uit over de precieze werking van GLP-1 
analogen op de afzonderlijke componenten van de glucosehuishouding in insuline 
resistente dieren, voor zover zij aantonen dat deze stoffen acuut het vermogen van 
insuline om glucose te verwijderen versterken en op de lange termijn de werking van 
insuline bevorderen op zowel glucose opname als productie. Aangezien insulineresistentie 
een complexe ziekte is en geassocieerd is met obesitas en hartziekten, is 
medicijnbehandeling die meerdere aspecten van de ziekte aangrijpt wenselijk. Daarom 
zijn de bevindingen dat chronische behandeling met CNTO736 leidt tot een daling van het 
lichaamsgewicht en een remming van de VLDL-triglyceride productie, veelbelovend. 
Aangezien de C57BL/6 muis geen geschikt model is voor het bestuderen van de 
vetstofwisseling, hebben wij het remmende effect van GLP-1M (de nieuwste versie van 
het CNTO molecuul) op de VLDL-triglyceride productie in hoofdstuk 4 verder onderzocht 
in APOE*3-Leiden muizen. APOE*3-Leiden muizen brengen het menselijk APOE*3-Leiden 
gen tot expressie, wat resulteert in een lipoproteïnen profiel gelijkend aan die van 
patiënten met dysbetalipoproteinemia, gekenmerkt door verhoogde plasma cholesterol 
en triglyceriden die voornamelijk beperkt zijn tot de VLDL/LDL-lipoproteïne-fractie. In 
tegenstelling tot andere muizen, reageren APOE*3-Leiden transgenen op verschillende 
medicijnen die lipiden niveaus verlagen op een vergelijkbare manier als in de mens en 
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worden daarom beschouwd als een "humaanachtig" diermodel voor onderzoek naar de 
effecten van medicijnen op verhoogde vetgehaltes in het bloed
10, 11
. Chronische 
toediening van GLP-1M in hoog vet gevoede APOE*3-Leiden muizen remt duidelijk de 
VLDL-triglyceride productie. Bovendien leidde chronische toediening van het 
geneesmiddel tot verlaagde cholesterol concentraties en een verhoogd HDL in dezelfde 
experimentele context. Onze gegevens suggereren dat GLP-1M krachtige anti-atherogene 
eigenschappen kan hebben in insuline resistente personen. Atherosclerose wordt 
gedreven door toegenomen (VLDL), cholesterol en triglyceride niveaus, vaak gepaard met 
lage HDL circulerende concentraties. HDL-deeltjes zijn anti-atherogeen, deels vanwege 
hun rol in omgekeerd cholesterol transport, maar ook vanwege hun anti-oxidatieve, anti-
ontsteking, anti-trombotische en anti-apoptotische eigenschappen
12-14
. Daarom is de 
verlaging van de plasma cholesterolconcentratie door GLP-1M  evenals de capaciteit om 
HDL-cholesterol niveaus te verhogen, beloftevol voor GLP-1M om als farmacologisch 
middel aderverkalking te voorkomen in metabole omstandigheden met een verhoogd 
risico daarop. Echter, de pathofysiologische gevolgen van de capaciteit van GLP-1M om de 
VLDL secretie te remmen is onzeker, omdat circulerende triglyceride spiegels 
onaangedaan waren, misschien als gevolg van een verminderde klaring van triglyceride uit 
het plasma.  
Belangrijk te vermelden is dat exendin-4 in hoofdstuk 3 op een vergelijkbare mate invloed 
heeft op de insulinegevoeligheid als CNTO736, maar geen invloed heeft op de VLDL-
productie in onze experimentele opzet. Dit suggereert dat GLP-1M stofspecifieke effecten 
kan hebben op de vetstofwisseling die de capaciteit versterken om macrovasculaire 
ziektes in hoog vet gevoede muizen (en mensen) te voorkomen. Aan de andere kant kan 
het worden gerelateerd aan de halfwaardetijd van GLP-1M in het bloed, welke aanzienlijk 
langer is dan exendin-4. Dit vraagstuk moet worden opgehelderd voordat een kordate 
conclusie kan worden getrokken over de effecten van GLP-1M op de vetstofwisseling.  
  
Alle perifere signalen van het maag-darmkanaal brengen metabole informatie over naar 
de hersenen. De belangrijkste structuren die betrokken zijn bij de controle van de 
glucosehuishouding zijn de hypothalamus en de hersenstam. De hypothalamus is het 
eerste integratiecentrum van hormonale informatie. Met name de nucleus arcuatus (ARC), 
gelegen in de mediobasale hypothalamus, bevat neuronen die gevoelig zijn voor zowel 
hormonen (ghreline, leptine, GLP-1) als voedingsstoffen (glucose, vetzuren). Verdere 
doelstructuren van de ARC zijn de kernen van de paraventriculaire en dorsomediale 
hypothalamus. Andere projecties van de ARC hebben het mediale preoptische gebied, de 
laterale hypothalamus en het ventromediane gebied als doel. Ten slotte hebben de 




Het is momenteel niet bekend in hoeverre de (metabole) effecten van circulerend GLP-1 
worden gereguleerd door centrale GLP-1-receptoren. In hoofdstuk 5 laten we zien dat 
GLP-1 behandeling de insulineresistentie van de glucosestofwisseling in hoog vet gevoede 
muizen vermindert voor een deel via de activering van GLP-1 receptoren gelegen in de 
hersenen. De neuronale circuits die worden geactiveerd door de toediening van GLP-1 en 
zijn metabole effecten reguleren, moeten nog worden geïdentificeerd. 
 Een mogelijkheid is dat GLP-1 in de hypothalamus de neuropeptide Y (NPY) route 
moduleert. Het is eerder gebleken dat directe toediening van GLP-1 in de hersenen de 
stimulerende effecten van NPY op de voedselinname volledig voorkomt, wat suggereert 
dat GLP-1 werkt door het blokkeren van NPY signalen om voedselconsumptie te 
remmen
15
. Acute toediening van NPY in de hersenen vermindert het vermogen van 
insuline om de endogene glucose productie te onderdrukken
16
. Bovendien worden 
diermodellen van obesitas en type 2 diabetes (met inbegrip van dieetgeïnduceerde 
zwaarlijvigheid) gekenmerkt door verhoogde NPY expressie in de hypothalamaire 
kernen
17, 18
. Om deze redenen is het denkbaar dat deze verhoogd actieve NPY neuronen 
betrokken zijn bij de pathofysiologie van verhoogde endogene productie van glucose in de 
aanwezigheid van hyperinsulinemie in deze modellen (en obese mensen). Eerder is laten 
zien dat GLP-1 in de hypothalamus de neuronale activiteit van NPY kan verminderen
19
. 
Daarom kan chronische toediening van GLP-1 of één van zijn analogen de door NPY 
geïnduceerde insulineresistentie hebben tegengewerkt om de bevindingen die we hier 
laten zien te verklaren. 
 De hypothalamus is echter niet alleen verantwoordelijk voor de integratie van 
perifere informatie afkomstig uit de darm. De hersenstam, in aanvulling op de interactie 
met de hypothalamaire paden, speelt ook een belangrijke rol in de regulering van de 
energiehuishouding. Gelegen in de hersenstam, ontvangt de nucleus tractus solitarius 
(NTS) via de vagus zenuw signalen uit het maag-darmkanaal. Daarom is het mogelijk dat 
GLP-1 (of zijn analogen) neuronen in de NTS in de hersenstam activeert via deze signalen 
om de glucosestofwisseling te moduleren. Ook veroorzaakt GLP-1 vagale afferente 
zenuwactiviteit om een hepatopancreatische reactie te veroorzaken, welke een 
belangrijke rol speelt bij de controle van het vrijkomen van insuline
20
. Het is denkbaar dat 
vagale afferente activiteit in dit verband niet beperkt is tot de alvleesklier, maar ook van 
invloed is op de lever en andere organen om de viscerale productie van glucose te 
reguleren. Bovendien vermindert vagale ablatie de anorectische effecten van perifere 
GLP-1 toediening
21
. In analogie, kan activering van de vagale afferentia door GLP-1 de 
glucosestofwisseling beïnvloeden. Naast invloed op afferente vezels, kan perifeer GLP-1 
ook rechtstreeks invloed hebben op de hersenstam. Net als de ARC, is de NTS gelegen in 
nauwe anatomische nabijheid van een circumventriculair orgaan met een onvolledige 
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bloed-hersen-barrière - het area postrema (AP) - en is daardoor in een ideale positie om te 
reageren op circulerende perifere signalen, zoals GLP-1. Inderdaad, toediening van GLP-1 
leidt tot een aanzienlijke toename van de signaalintensiteit in de AP van nuchtere muizen, 
wat duidt op een toename van de neuronale activiteit in de hersenstam
22
. 
 Ondanks de toenemende data van het belang van de darm-hersen-as in het 
controleren van de glucosehuishouding, blijft het mogelijk dat GLP-1 rechtstreeks op de 
lever en andere perifere weefsels werkt via een structureel en functioneel verschillende 
GLP-1R. Eerder is gerapporteerd dat GLP-1 insulineachtige acties heeft in lever en 




Ten slotte werd in hoofdstuk 6, het potentieel van twee nieuwe ontwikkelde analogen, 
Obinepitide en TM30339, onderzocht. De resultaten laten zien dat chronische behandeling 
met deze geneesmiddelen gunstige effecten heeft op de insulineresistentie in hoog vet 
gevoede muizen, met betrekking tot de insuline gereguleerde glucose opname en 
productie. Beide stoffen, in overeenstemming met hun eigenschappen als anti-obesitas 
geneesmiddelen, verminderden ook het lichaamsgewicht (door het verlagen van de totale 
vetmassa) in onze experimentele opzet. Aangezien insulinegevoeligheid en gewichtsverlies 
sterk gecorreleerd zijn
25
, zou het effect van het laatste de onderliggende oorzaak kunnen 
zijn voor de vermindering van de insulineresistentie. Gepaard gevoede studies kunnen 
hierop het antwoord geven. Echter, onafhankelijk van het mechanisme, en zeer belangrijk, 
laten onze resultaten zien dat de metabole effecten van Obinepitide en TM30339 niet 
afzwakken tijdens chronische behandeling, wat ze waardevolle therapieën maken om 
zowel obesitas als insulineresistentie te behandelen. 
  
Concluderend, hebben we van een verscheidenheid aan darmhormonen of analogen 
daarvan aangetoond dat ze gunstige effecten hebben op de glucosestofwisseling. Onze 
diermodellen roepen echter nog steeds vragen op die in meer detail moeten worden 
verduidelijkt, alvorens de stoffen kunnen worden gebruikt in de klinische setting. 
Langdurige behandelingen kunnen ook bijwerkingen uiten, welke gerelateerd zijn aan 
maaglediging en misselijkheid, die gemeld zijn voor GLP-1 en verwante moleculen. In 
reactie op de postmarketing meldingen van acute alvleesklierontsteking bij patiënten die 
exenatide gebruiken, heeft de Amerikaanse Food en Drug Administration (FDA) een 
waarschuwing aan de etikettering van Byetta toegevoegd in 2007. In augustus 2008 
werden vier extra sterfgevallen als gevolg van alvleesklierontsteking bij gebruikers van 
exenatide gerapporteerd aan de FDA. Hoewel er geen duidelijke relatie werd vastgesteld, 




 In de afgelopen tien jaar wijst een toenemende hoeveelheid bewijsmateriaal 
erop dat de darm-hersen-as een belangrijke speler is in het controleren van de 
glucosehuishouding. Peptiden zoals GLP-1 zijn aan het licht gekomen als belangrijke 
factoren die metabole informatie kunnen overbrengen naar de hersenen en bovendien de 
endogene glucose productie en opname reguleren. Het meer in het detail ophelderen van 
de moleculaire gebeurtenissen in de hersenen die ten grondslag liggen aan de effecten 
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